ES2535155T3 - Moduladores de receptores de estrógeno y usos de los mismos - Google Patents
Moduladores de receptores de estrógeno y usos de los mismos Download PDFInfo
- Publication number
- ES2535155T3 ES2535155T3 ES14155086.3T ES14155086T ES2535155T3 ES 2535155 T3 ES2535155 T3 ES 2535155T3 ES 14155086 T ES14155086 T ES 14155086T ES 2535155 T3 ES2535155 T3 ES 2535155T3
- Authority
- ES
- Spain
- Prior art keywords
- phenyl
- acid
- acrylic
- indazol
- phenylbut
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002834 estrogen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract description 115
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract description 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 abstract description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 7
- 229910052736 halogen Inorganic materials 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 1H – indazol – 5-yl Chemical group 0.000 description 428
- 239000002253 acid Substances 0.000 description 390
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 381
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 247
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 89
- 102100038595 Estrogen receptor Human genes 0.000 description 16
- 101710196141 Estrogen receptor Proteins 0.000 description 16
- 238000003556 assay Methods 0.000 description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 13
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 11
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 125000005504 styryl group Chemical group 0.000 description 6
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 5
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 4
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 description 2
- HVCAUTAOQALMGO-UHFFFAOYSA-N 1-(oxan-2-yl)indazole Chemical compound O1CCCCC1N1C2=CC=CC=C2C=N1 HVCAUTAOQALMGO-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- GWQOOADXMVQEFT-UHFFFAOYSA-N 2,5-dimethyl thiophene Natural products CC1=CC=C(C)S1 GWQOOADXMVQEFT-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 2
- 238000004172 nitrogen cycle Methods 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N pentanoic acid group Chemical group C(CCCC)(=O)O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- JOXWDTFEGLTGOU-FDTZCEHLSA-N (e)-3-[4-[(e)-1-(1h-indazol-5-yl)-2-(2-methylsulfonylphenyl)but-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=C(S(C)(=O)=O)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(O)=O)C=C1 JOXWDTFEGLTGOU-FDTZCEHLSA-N 0.000 description 1
- WCLZCRRVBJRXFV-ZGCBMYLXSA-N (e)-3-[4-[(e)-1-(1h-indazol-5-yl)-2-(3-methylsulfonylphenyl)but-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC(S(C)(=O)=O)=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(O)=O)C=C1 WCLZCRRVBJRXFV-ZGCBMYLXSA-N 0.000 description 1
- XOLXZLWSZOFHDR-QNRQJRPTSA-N (e)-3-[4-[(e)-1-(1h-indazol-5-yl)-2-phenylbut-1-enyl]phenyl]-n-propan-2-ylprop-2-enamide Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(=O)NC(C)C)C=C1 XOLXZLWSZOFHDR-QNRQJRPTSA-N 0.000 description 1
- ODSVCUBDIGOMJE-AEELIEMKSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]-n-methoxy-n-methylprop-2-enamide Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(=O)N(C)OC)C=C1 ODSVCUBDIGOMJE-AEELIEMKSA-N 0.000 description 1
- SHCDBAZDRQBJRR-LPOJXSLPSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]-n-methylprop-2-enamide Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(=O)NC)C=C1 SHCDBAZDRQBJRR-LPOJXSLPSA-N 0.000 description 1
- BGLXGTBAKZALGC-LPOJXSLPSA-N (e)-3-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]-n-methylsulfonylprop-2-enamide Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(=O)NS(C)(=O)=O)C=C1 BGLXGTBAKZALGC-LPOJXSLPSA-N 0.000 description 1
- SUEWCAJDTPHOHP-QBMVERNNSA-N (e)-3-[4-[(e)-2-cyclobutyl-1-(1-methylindazol-5-yl)-2-phenylethenyl]phenyl]-n-methylprop-2-enamide Chemical compound C1=CC(/C=C/C(=O)NC)=CC=C1C(\C=1C=C2C=NN(C)C2=CC=1)=C(C=1C=CC=CC=1)\C1CCC1 SUEWCAJDTPHOHP-QBMVERNNSA-N 0.000 description 1
- WSZSSKLHFAETQF-LVMHYTKUSA-N (e)-n-hydroxy-3-[4-[(e)-1-(1h-indazol-5-yl)-2-phenylbut-1-enyl]phenyl]prop-2-enamide Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(\C=C\C(=O)NO)C=C1 WSZSSKLHFAETQF-LVMHYTKUSA-N 0.000 description 1
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 1
- SWEICGMKXPNXNU-UHFFFAOYSA-N 1,2-dihydroindazol-3-one Chemical compound C1=CC=C2C(O)=NNC2=C1 SWEICGMKXPNXNU-UHFFFAOYSA-N 0.000 description 1
- NITLYOQFVAUMHG-UHFFFAOYSA-N 1-bromo-2-fluoro-3-phenoxybenzene Chemical compound FC1=C(Br)C=CC=C1OC1=CC=CC=C1 NITLYOQFVAUMHG-UHFFFAOYSA-N 0.000 description 1
- JUSIZHSBPCWCMC-UHFFFAOYSA-N 1-bromo-2-methyl-4-phenoxybenzene Chemical compound C1=C(Br)C(C)=CC(OC=2C=CC=CC=2)=C1 JUSIZHSBPCWCMC-UHFFFAOYSA-N 0.000 description 1
- GVLRTOYGRNLSDW-UHFFFAOYSA-N 1h-pyrazolo[3,4-b]pyridine Chemical compound C1=CC=C2C=NNC2=N1 GVLRTOYGRNLSDW-UHFFFAOYSA-N 0.000 description 1
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 1
- FKIUHOPVYKKXAP-UHFFFAOYSA-N 2-bromo-1-methyl-4-phenoxybenzene Chemical compound C1=C(Br)C(C)=CC=C1OC1=CC=CC=C1 FKIUHOPVYKKXAP-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- BWEASHSUWJITRO-WNAAXNPUSA-N 3-[4-[(e)-1-(1h-indazol-5-yl)-2-phenylbut-1-enyl]phenyl]propanoic acid Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C1=CC=C(CCC(O)=O)C=C1 BWEASHSUWJITRO-WNAAXNPUSA-N 0.000 description 1
- GREWZYRZMVYLBQ-UHFFFAOYSA-N 4-bromo-1-fluoro-2-phenoxybenzene Chemical compound FC1=CC=C(Br)C=C1OC1=CC=CC=C1 GREWZYRZMVYLBQ-UHFFFAOYSA-N 0.000 description 1
- RUPZRQFTQRQTHI-UHFFFAOYSA-N 4-bromo-1-methyl-2-phenoxybenzene Chemical compound CC1=CC=C(Br)C=C1OC1=CC=CC=C1 RUPZRQFTQRQTHI-UHFFFAOYSA-N 0.000 description 1
- OJJUNYGUSAOFNY-UHFFFAOYSA-N 4-bromo-2-fluoro-1-phenoxybenzene Chemical compound FC1=CC(Br)=CC=C1OC1=CC=CC=C1 OJJUNYGUSAOFNY-UHFFFAOYSA-N 0.000 description 1
- YCVUCSIVIYZHGC-UHFFFAOYSA-N 4-bromo-2-methyl-1-phenoxybenzene Chemical compound CC1=CC(Br)=CC=C1OC1=CC=CC=C1 YCVUCSIVIYZHGC-UHFFFAOYSA-N 0.000 description 1
- YTNDJUBXSVSRQK-UHFFFAOYSA-N 4-fluoro-1h-indazole Chemical compound FC1=CC=CC2=C1C=NN2 YTNDJUBXSVSRQK-UHFFFAOYSA-N 0.000 description 1
- DBJMEBUKQVZWMD-UHFFFAOYSA-N 4-methyl-1,4-benzoxazin-3-one Chemical compound C1=CC=C2N(C)C(=O)COC2=C1 DBJMEBUKQVZWMD-UHFFFAOYSA-N 0.000 description 1
- UJMLVYSZLDFCPE-SHHOIMCASA-N 5-[(e)-1-(1h-indazol-5-yl)-2-phenylbut-1-enyl]-2,3-dihydro-1h-indene-2-carboxylic acid Chemical compound C=1C=C2CC(C(O)=O)CC2=CC=1/C(C=1C=C2C=NNC2=CC=1)=C(/CC)C1=CC=CC=C1 UJMLVYSZLDFCPE-SHHOIMCASA-N 0.000 description 1
- MMLFMEZBDVFWTR-ORIPQNMZSA-N 5-[(e)-2-phenyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]but-1-enyl]-1h-indazole Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C(C=C1)=CC=C1OCCN1CCCC1 MMLFMEZBDVFWTR-ORIPQNMZSA-N 0.000 description 1
- GYVTZUSRPMLUHN-LVMHYTKUSA-N 5-[(e)-2-phenyl-1-[4-[(e)-2-(2h-tetrazol-5-yl)ethenyl]phenyl]but-1-enyl]-1h-indazole Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C(C=C1)=CC=C1\C=C\C=1N=NNN=1 GYVTZUSRPMLUHN-LVMHYTKUSA-N 0.000 description 1
- LKKCIYSZBJMBNB-LHLOQNFPSA-N 5-[4-[(e)-2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-enyl]phenyl]-1,2-oxazol-3-one Chemical compound C=1C=C(F)C=C(Cl)C=1C(/CC)=C(C=1C=C2C=NNC2=CC=1)\C(C=C1)=CC=C1C1=CC(O)=NO1 LKKCIYSZBJMBNB-LHLOQNFPSA-N 0.000 description 1
- XONKJZDHGCMRRF-UHFFFAOYSA-N 7-fluoro-1h-indole Chemical compound FC1=CC=CC2=C1NC=C2 XONKJZDHGCMRRF-UHFFFAOYSA-N 0.000 description 1
- QPLLPLLBBSWRTM-UHFFFAOYSA-N 7-methoxy-1-benzofuran Chemical compound COC1=CC=CC2=C1OC=C2 QPLLPLLBBSWRTM-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150026303 HEX1 gene Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- 229910002666 PdCl2 Inorganic materials 0.000 description 1
- 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229910006069 SO3H Inorganic materials 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- HDZRDZCQFYUOHE-UHFFFAOYSA-N ditert-butyl-(1-phenylindol-2-yl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC2=CC=CC=C2N1C1=CC=CC=C1 HDZRDZCQFYUOHE-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- HZAIHFIZXXSPFA-UHFFFAOYSA-N ethynylcyclopropane Chemical compound [C+]#CC1CC1 HZAIHFIZXXSPFA-UHFFFAOYSA-N 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 125000004500 isothiazol-4-yl group Chemical group S1N=CC(=C1)* 0.000 description 1
- HZVPJXOQDCOJRJ-UHFFFAOYSA-N isoxazolin-5-one Chemical compound O=C1C=CNO1 HZVPJXOQDCOJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- LXKVXDHWSHNDCA-UHFFFAOYSA-N trimethyl-[2-[4-methyl-1-(oxan-2-yl)indazol-5-yl]ethynyl]silane Chemical compound N1=CC=2C(C)=C(C#C[Si](C)(C)C)C=CC=2N1C1CCCCO1 LXKVXDHWSHNDCA-UHFFFAOYSA-N 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/16—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
Un compuesto que tiene la estructura de Fórmula (XII):**Fórmula** en donde, X 1 es CH, CR3 o N; X2 es N, CH, o CR3; Z es -OH o -OR10; R2 es C1-C4alquilo, C1-C4fluoroalquilo, C1-C4deuteroalquilo, C3-C6cicloalquilo, o -C1-C4alquileno-W; W es hidroxi, halógeno, CN, C1-C4alquilo, C1-C4haloalquilo, C1-C4alcoxi, C1-C4haloalcoxi, y C3-C6cicloalquilo; cada R3 es independientemente halógeno, C1-C4alquilo, o C1-C4fluoroalquilo; cada R4 es independientemente halógeno, -CN, -OR9, -S(>=O)2R10, C1-C4alquilo, C1-C4fluoroalquilo, o C1-C4heteroalquilo; cada R5 es independientemente halógeno, -CN, -OR9, -S(>=O)2R10, C1-C4alquilo, C1-C4fluoroalquilo, o C1-C4heteroalquilo; R6 es H, C1-C4alquilo, o halógeno; R7 es H, C1-C4alquilo, o halógeno; R9 es H, C1-C6alquilo, C1-C6fluoroalquilo, o C3-C6cicloalquilo; R10 es C1-C6alquilo; m es 0, 1, o 2; n es 0, 1, 2, 3, o 4; y p es 0, 1, o 2; o una sal farmacéuticamente aceptable, o N-óxido del mismo.
Description
E14155086
16-04-2015
El compuesto de Fórmula (II) puede tener la estructura de Fórmula (III) o (IV):
El compuesto de Fórmula (I) puede tener la estructura de Fórmula (V):
El compuesto de Fórmula (I) puede tener la estructura de Fórmula (XI):
En algunos ejemplos, Y es –C(=O)–Z, tetrazolilo, piperidinilo sustituido opcionalmente, pirrolidinilo sustituido opcionalmente, –NR8R8’ , –AR–OH, –SO3H, y –P(=O)(OH)2 en donde AR es fenilo o heteroarilo monocíclico; Z es –OH, –OR10 , –NR8R8’ , – 10 NR8S(=O)2R10, o –NHOH; R8 y R8’ es independientemente H, C1–C6alquilo, C2–C6alquenilo, o C2–C6alquinilo.
En algunos ejemplos, R8 y R8’ es independientemente H, C1–C6alquilo sustituido o no sustituido, C2–C6alquenilo sustituido o no sustituido, C2–C6alquilo sustituido o no sustituido, C1–C6fluoroalquilo sustituido o no sustituido, C1–C6heteroalquilo sustituido o no sustituido, C3–C6cicloalquilo sustituido o no sustituido, fenilo sustituido o no sustituido, heteroarilo monocíclico sustituido o no sustituido, o bencilo sustituido o no sustituido,. En algunos ejemplos, R8 y R8’ son independientemente H, C1– 15 C6alquilo, C2–C6alquenilo, C2–C6alquinilo, C1–C6–fluoroalquilo, C1–C6heteroalquilo, C3–C6cicloalquilo, fenilo sustituido o no sustituido, heteroarilo monocíclico sustituido o no sustituido, o bencilo sustituido o no sustituido,. En algunos ejemplos, R8 es H, C1–C6alquilo, C1–C6–fluoroalquilo, C1–C6heteroalquilo, C3–C6cicloalquilo, fenol sustituido o no sustituido, heteroarilo monocíclico sustituido o no sustituido, o bencilo sustituido o no sustituido,. En algunos ejemplos , R8 es H, C1–C6alquilo, o
E14155086
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 1
-
3–(4–((E)–1–(1H–indazol–5–il)–2–fenilbut–1– en–1–il)fenil)acrilato de (E)–Etilo
imagen30 423
- 2
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)acrílico 395
- 3
-
Ácido (E)–3–(4–((E)–1–(1H– Benzo[d][1,2,3]triazol–5–il)–2–fenilbut–1–en– 1–il)fenil) acrílico
imagen31 396
- 4
-
Ácido (E)–3–(4–((E)–2–(4–Fluorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen32 413
- 5 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–6–il)–2– fenilbut–1–en–1–il)fenil)acrílico
imagen33 395
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 6
-
Ácido (E)–3–(4–((E)–2–(4–Clorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen34 429
- 7
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–metoxifenil)but–1–en–1–il)fenil)acrílico 425
- 8
- Ácido (E)–3–(4–((E)–2–(3– (Hidroximetil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 425
- 9
-
Ácido (E)–3–(4–((E)–2–(4– (Hidroximetil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico
imagen35 425
- 10
- Ácido (E)–3–(4–((E)–2–(2– (Hidroximetil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 425
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 11
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (o–toluil)but–1–en–1–il)fenil)acrílico
imagen36 409
- 12
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (m–toluil)but–1–en–1–il)fenil)acrílico
imagen37 409
- 13
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (p–toluil)but–1–en–1–il)fenil)acrílico 409
- 14
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metoxifenil)but–1–en–1–il)fenil)acrílico
imagen38 425
- 15
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–metoxifenil)but–1–en–1–il)fenil)acrílico 425
16-04-2015
(continuación) E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 16
-
Ácido ((E)–3–(4–((E)–2–(2–Clorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen39 429
- 17
- Ácido (E)–3–(4–((E)–2–(3–Clorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 429
- 18 *
- Ácido (E)–3–(4–((E)–1–(1H–Indozol–4–il)–2– fenilbut–1–en–1–il)fenil)acrílico 395
- 19
- Ácido (E)–3–(4–((E)–2–(2–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 413
- 20
- Ácido (E)–3–(4((E)–2–(3–Fluorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 413
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 21 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–4–il)–2– (o–toluil)but–1–en–1–il)fenil)acrílico
imagen40 409
- 22 *
- Ácido (E)–3–(4–((E)–2–(2–Clorofenil)–1–(1H– indazol–4–il)but–1–en–1–il)fenil)acrílico 429
- 23 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (tiofen–2–il)but–1–en–1–il)fenil)acrílico 401
- 24 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (tiofen–3–il)but–1–en–1–il)fenil)acrílico 401
- 25 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (piridin–2–il)but–1–en–1–il)fenil)acrílico
imagen41 396
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 26
-
Ácido (E)–3–(4–((E)–2–(2–Etilfenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen42 423
- 27
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–(trifluorometil)fenil)but–1–en–1– il)fenil)acrílico 463
- 28 *
- Ácido (E)–3–(4–((E)–2–([1,1’–Bifenil]–2–il)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 471
- 29
- Ácido (E)–3–(4–((E)–4–Cloro–1–(1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 429
- 30 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1H–indazol–4–il)but–1–en–1– il)fenil)acrílico 447
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 31 *
-
Ácido (E)–3–(4–((E)–2–(2–Fluorofenil)–1–(1H– indazol–4–il)but–1–en–1–il)fenil)acrílico
imagen43 413
- 32
-
Ácido (E)–3–(4((E)–2–(2–Cianofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen44 420
- 33
-
Ácido (E)–3–(4–{(E)–2–(2,4–Difluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen45 431
- 34
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–3– Fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen46 447
- 35
- Ácido (E)–3–(4–((E)–2–Ciclopropilo–1–(1H– indazol–5–il)–2–fenilvinil)fenil)acrílico 407
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 36
-
Ácido (E)–3–(4–((E)–2–(4–Fluoro–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen47 427
- 37
-
Ácido (E)–3–(4–((E)–2–(2,6–Difluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen48 431
- 38
- Ácido (E)–3–(4–((E)–2–(2,6–Diclorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 463
- 39
- Ácido (E)–3–(4–((E)–4,4,4–Trideutero–1–(1H– indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 398
- 40
-
Ácido (E)–3–(4–((E)–2–(4–Fluoro–3– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen49 427
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 41
-
Ácido (E)–3–(4–((E)–2–(5–Fluoro–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen50 427
- 42
- Ácido (E)–3–(4–((E)–2–(2,3–Difluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 431
- 43
- Ácido (E)–3–(4–((E)–2–(2,5–Difluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 431
- 44
- Ácido (E)–3–(4–((E)–2–(2–Cloro–5– fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 447
- 45
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–6– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen51 443
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 46
-
Ácido (E)–3–(4–((E)–1–(7–Cloro–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen52 429
- 47
- Ácido (E)–3–(4–((E)–1–(4–Metil–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 409
- 48
- Ácido (E)–3–(4–((E)–1–(7–Metil–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 409
- 49
- Ácido (E)–3–(4–((E)–1–(6–Metil–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 409
- 50 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (naftalen–1–il)but–1–en–1–il)fenil)acrílico 445
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 51
-
Ácido (E)–3–(4–((E)–1–(3–Metil–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen53 409
- 52
- Ácido (E)–3–(4–((E)–1–(3–Cloro–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 429
- 53
-
Ácido (E)–3–(4–((E)–2–(4–(Cloro–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen54 443
- 54
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilprop–1–en–1–il)fenil)acrílico 381
- 55
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilpent–1–en–1–il)fenil)acrílico
imagen55 409
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 56 *
-
Ácido (E)–3–(4–((E)–2–Fenil–1–(1H– pirazolo[3,4–b]piridin–4–il}but–1–en–1– il)fenil)acrílico
imagen56 396
- 57
- Ácido (E)–3–(4–((E)–2–(3–Cianofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 420
- 58
- Ácido (E)–3–(4–((E)–2–(4–Cianofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 420
- 59
- Ácido (E)–3–(4–((E)–4–Hidroxi–1–(1H– indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 411
- 60
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–4– metoxi–2–fenilbut–1–en–1–il)fenil)acrílico
imagen57 425
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 61
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–3– metoxi–2–fenilprop–1–en–1–il)fenil)acrílico
imagen58 411
- 62 *
- Ácido (E)–3–(4–((E)–2–(4– (Dimetilamino)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 438
- 63
-
Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen59 413
- 64
-
Ácido (E)–3–(4–((E)–1–(1H–)Indol–5–il)–2– fenilbut–1–en–1–il)fenil)acrílico
imagen60 394
- 65
- Ácido (E)–3–(4–((E)–1–(6–Cloro–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 429
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 66 *
-
Ácido (E)–3–(4((E)–1–(2–Oxo–2,3– dihidrobenzo[d]oxazol–6–il)–2–fenilbut–1–en– 1–il)fenil)acrílico
imagen61 412
- 67 *
- Ácido (E)–3–(4–((E)–2.Fenil–1–(1H– pirazolo[3,4–b]piridin–5–il)but–1–en–1– il)fenil)acrílico 396
- 68 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(1H– pirrolo[2,3–b]piridin–5–il)but–1–en–1– il)fenil)acrílico 395
- 69
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–4– metil–2–fenilpent–1–en–1–il)fenil)acrílico 423
- 70 *
- Ácido (E)–3–(4–((E)–2–Ciclopropilo–1–(1H– indazol–4–il)–2–fenilvinil)fenil)acrílico 407
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 71 *
-
Ácido (E)–3–(4–((E)–2–(2–Clorofenil)–2– ciclopropilo–1–(1H–indazol–4– il)vinil)fenil)acrílico
imagen62 441
- 72
-
Ácido (E)–3–(4–((E)–1–(1H– Benzo[d][1,2,3]triazol–5–il)–2–(2–cloro–4– Fluorofenil)but–1–en–1–il)fenil)acrílico
imagen63 448
- 73 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclopropilo–1–(1H–indazol–4– il)vinil)fenil)acrílico 459
- 74
-
Ácido (E)–3–(4–((E)–1–(4–Cloro–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen64 429
- 75 *
-
Ácido (E)–3–(4–((E)–1–(2–Oxo–2,3– dihidrobenzo[d]tiazol–6–il)–2–fenilbut–1–en– 1–il)fenil)acrílico
imagen65 428
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 76
-
Ácido (E)–3–(4–((E)–2–Ciclopentilo–1–(1H– indazol–5–il)–2–fenilvinil)fenil)acrílico
imagen66 435
- 77
-
Ácido (E)–3–(4–((E)–2–Ciclohexilo–1–(1H– indazol–5–il)–2–fenilvinil)fenil)acrílico
imagen67 449
- 78
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–3– metil–2–fenilbut–1–en–1–il)fenil)acrílico 409
- 79
-
Ácido (E)–3–(4–((E)–3–Ciclopropilo–1–(1H– indazol–5–il)–2–fenilprop–1–en–1– il)fenil)acrílico y
imagen68 421
- 80
- Ácido (E)–3–(4–((E)–2–(2–Clorofenil)–2– ciclopropilo–1–(1H–indazol–5– il)vinil)fenil)acrílico 441
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 81 *
-
Ácido (E)–3–(4–((E)–2–Fenil–1–(1H–il)but–1– en–1–il)fenil)acrílico
imagen69 396
- 82
- Ácido (E)–3–(4–((E)–1–(6–fluoro–1H–indazol– 5–il)–2–fenilbut–1–en–1–il)fenil)acrílico 413
- 83 *
-
Ácido (E)–3–(4–((E)–1–(1H– Benzo[d]imidazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen70 395
- 84
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilhex–1–en–1–il)fenil)acrílico
imagen71 423
- 85
-
Ácido (E)–3–(4–((E)–3–Ciclopentilo–1–(1H– indazol–5–il)–2–fenilprop–1–en–1– il)fenil)acrílico
imagen72 449
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 86 *
-
Ácido (E)–3–(4–((E)–1–(6–Fluoro–1H– indazol–4–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen73 413
- 87
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(4–fluoro–1H–indazol–5–il)but– en–1–il)fenil)acrílico
imagen74 465
- 88 *
-
Ácido (E)–3–(4–((E)–1–(1H– Benzo[d][1,2,3]triazol–4–il)–2–fenilbut–1–en– 1–il)fenil)acrílico
imagen75 396
- 89 *
- Ácido (E)–3–(4–((E)–1–(1H– Benzo[d][1,2.3]triazol–4–il)–2–(2–cloro–4– Fluorofenil)but–1–en–1–il)fenil)acrílico 448
- 90 *
- Ácido (E)–3–(4–((E)–1–(3–Oxo–2,3– dihidroisoquinolin–6–il)–2–fenilbut–1–en–1– il)fenil)acrílico 422
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 91
-
Ácido (E)–3–(4–((E)–1–(7–Fluoro–1H– indazol–5–il)–2–fenilbut–1–en–1– il)penil)acrílico
imagen76 413
- 92
- Ácido (E)–3–4–((E)–1–(7–Fluoro–1H–indol–5– il)–2–fenilbut–1–en–1–il)fenil)acrílico 412
- 93
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1H–indazol–5–il)–4–metilpent– 1–en–1–il)fenil)acrílico 475
- 94
- Ácido (E)–3–(4–((Z)–3,3–Difluoro–1–(1H– indazol–5–il)–2–fenilprop–1–en–1– il)fenil)acrílico 417
- 95
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(7–fluoro–1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico
imagen77 465
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 96 *
-
Ácido (E)–3–(4–((E)–2–(Benzofuran–4–il)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen78 435
- 97 *
-
Ácido (E)–3–(4–((E)–1–(1–Oxo–1,2– dihidroquinolin–6–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen79 422
- 98
-
Ácido (E)–3–(4–((E)–4–Fluoro–1–(1H– indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen80 413
- 99
-
Ácido (E)–3–(4–((E)–4–Cloro–2–(2–cloro–4– Fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen81 481
- 100 *
-
Ácido (E)–3–(4–((E)–1–(2–Oxo–1,2,3,4– tetrahidroquinolin–6–il)–2–fenilbut–1–en–1– il)fenilo]acrílico
imagen82 424
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 101 *
-
Ácido (E)–3–(4–((E)–1–(2–Oxo–2,4–dihidro– 1H–benzo[d][1,3]oxazin–6–il)–2–fenilbut–1– en–1–il)fenil)acrílico
imagen83 426
- 102 *
- Ácido (E)–3–(4–((E)–1–(2–Oxo–1,2– dihidroquinolin–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 422
- 103 *
- Ácido (E)–3–(4–((E)–1–(3–Oxo.3,4–dihidro– 2H–benzo[b][1,4]tiazin–7–il)–2–fenilbut–1–en– 1–il)fenil)acrílico 442
- 104 *
- Ácido (E)–3–(4–((E)–1–(3–Oxoisoindolin–5– il)–2–fenilbut–1–en–1–il)fenil)acrílico 410
- 105 *
- Ácido (E)–3–(4–((E)–1–(2–Oxo–1,2– dihidroquinolin–6–il)–2–fenilbut–1–en–1– il)fenil)acrílico 422
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 106
-
Ácido (E)–3–(4–((Z)–3,3,3–Trifluoro–1–(1H– indazol–5–il)–2–fenilprop–1–en–1– il)fenil)acrílico
imagen84 no observado
- 107 *
- Ácido (E)–3–(4–((E)–1–(3–Oxo–3,4–dihidro– 2H–benzo[b][1,4]oxazin–7–il)–2–fenilbut–1– en–1–il)fenil)acrílico no observado
- 108
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(4–floro–2–metilfenil)but–1– en–1–il)fenil)acrílico 445
- 109
- Ácido (E)–3–(4–((E)–2–(4–Cloro–2– metilfenil)–1–(4–fluoro–1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 461
- 110 *
- Ácido (E)–3–(4–((E)–1–(1–Oxoisoindolin–5– il)–2–fenilbut–1–en–1–il)fenil)acrílico 410
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 111
-
Ácido (E)–3–(4–((E)–2–Ciclopropilo–1–(4– fluoro–1H–indazol–5–il)–2–(4–fluoro–2– metilfenil)vinil)fenil)acrílico
imagen85 457
- 112
- Ácido (E)–3–(4–((E)–2–(4–Cloro–2– metilfenil)–2–ciclopropilo–1–(4–fluoro–1H– indazol–5–il)vinil)fenil)acrílico 473
- 113
- Ácido (E)–3–(4–((E)–1–(4–Cloro–1H–indazol– 5–il)–2–(2–cloro–4–Fluorofenil)but–1–en–1– il)fenil)acrílico 481
- 114
- Ácido (E)–3–(4–((Z)–2–(2–Cloro–4– Fluorofenil)–3,3–difluoro–1–(1H–indazol–5– il)prop–1–en–1–il)fenil)acrílico 469
- 115
-
Ácido (E)–3–(4–((E)–2–Ciclopropilo–1–(4– fluoro–1H–indazol–5–il)–2– fenilvinil)fenil)acrílico
imagen86 425
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 116
-
Ácido (E)–3–(4–((E)–4–Cloro–1–(4–fluoro– 1H–indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen87 447
- 117
- Ácido (E)–3–(4–((E)–4–Cloro–2–(2–cloro–4– Fluorofenil)–1–(4–fluoro–1H–indazol–5– il)but–1–en–1–il)fenil)acrílico 499
- 118 *
-
Ácido (E)–3–(4–((E)–2–(4–Fluorofenil)–1– (quinolin–6–il)but–1–en–1–il)fenil)acrílico
imagen88 406
- 119
-
Ácido (E)–3–(4–((E)–4–Fluoro–2–(4– Fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen89 431
- 120 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(1H– pirazolo[4,3–b]piridin–5–il)but–1–en–1– il)fenil)acrílico 396
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 121
-
Ácido (E)–3–(4–((E)–4–Fluoro–1–(4–fluoro– 1H–indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen90 431
- 122 *
- Ácido (E)–3–(4–((E)–1–(2–Oxo–2,3–dihidro– 1H–benzo[d]imidazol–5–il)–2–fenilbut–1–en– 1–il)fenil)acrílico 411
- 123 *
- Ácido (E)–3–(4–((E)–1–(Naftalen–2–il)–2– fenilbut–1–en–1–il)fenil)acrílico 404
- 124 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(quinoxalin– 6–il)but–1–en–1–il)fenil)acrílico 407
- 125 *
-
Ácido (E)–3–(4–((E)–2–Fenil–1–(pirazolo[1,5– a]piridin–5–il)but–1–en–1–il)fenil)acrílico
imagen91 395
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 126 *
-
Ácido (E)–3–(4–((E)–1–(Imidazo[1,2–a]piridin– 6–il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen92 395
- 127 *
- Ácido (E)–3–(4–((E)–1–([1,2,4]–Triazolo[4,3– a]piridin–6–il)–2–fenilbut–1–en–1– il)fenil)acrílico 396
- 128 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d][1,3]dioxol– 5–il)–3–fenilbut–1–en–1–il)fenil)acrílico
imagen93 397 (ES–)
- 129 *
- Ácido (E)–3–(4–((E)–1–(Imidazo[1,2–a]piridin– 6–il)–2–(o–toluil)but–1–en–1–il)fenil)acrílico 409
- 130 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–6–il)– 2–fenilbut–1–en–1–il)fenil)acrílico 412
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 131 *
-
Ácido (E)–3–(4–((E)–1–([1,2,4]Triazolo[1,5– a]piridin–6–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen94 396
- 131 *
-
Ácido (E)–3–(4((E)–2–Fenil–1–(tetrazolo[1,5– a]piridin–6–il)but–1–en–1–il)fenil)acrílico
imagen95 397
- 133 *
- Ácido (E)–3–(4–((E)–1–(Imidazo[1,5–a]piridin– 6–il)–2–fenilbut–1–en–1–il)fenil)acrílico 395
- 134 *
- Ácido (E)–3–(4–((E)–1–([1,2,4]Triazolo[4,3– a]piridin–7–il)–2–fenilbut–1–en–1– il)fenil)acrílico 396
- 135 *
- Ácido (E)–3–(4–((E)–1–(Imidazo[1,5–a]piridin– 7–il)–2–fenilbut–1–en–1–il)fenil)acrílico 395
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 136 *
-
Ácido (E)–3–(4–((E)–1–([1,2,4]Triazolo[1,5– a]piridin–7–il)–2–fenilbut–1–en–1– il)fenil)acrílico
imagen96 396
- 137 *
- Ácido (E)–3–(4–((E)–1– (Benzo[c][1,2,5]oxadiazol–5–il)–2–fenilbut–1– en–1–il)fenil)acrílico 397
- 138 *
- Ácido (E)–3–(4–((E)–1–([1,2,3]Triazolo[1,5– a]piridin–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 396
- 139
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–5– metoxi–2–fenilpent–1–en–1–il)fenil)acrílico 439
- 140
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–6– metoxi–2–fenitex–1–en–1–il)fenil)acrílico
imagen97 453
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 141 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–fenilbut–1–en–1–il)fenil)acrílico
imagen98 412
- 142 *
- Ácido (E)–3–(4–((E)–1–(Benzo[b]tiofen–2–il)– 2–fenilbut–1–en–1–il)fenil)acrílico 409
- 143 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(1–fenil–1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 471
- 144 *
- Ácido (E)–3–(4–((E)–1– (Benzo[c][1,2,5]tiadiazol–5–il)–2–fenilbut–1– en–1–il)fenil)acrílico 413
- 145 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(1–(piridin–3– il)–1H–indazul–5–il)but–1–en–1–il)fenil)acrílico 472
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 146 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]oxazol–5–il)– 2–fenilbut–1–en–1–il)fenil)acrílico
imagen99 396
- 147 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–fenoxifenil)but–1–en–1–il)fenil)acrílico 487
- 148 *
-
Ácido (E)–3–(4–((E)–2–Fenil–1–(pirazolo[1,5– a]piridin–3–il)but–1–il)fenil)acrílico
imagen100 395
- 149 *
- Ácido (E)–3–(4–((E)–2–Fenil–1–(1H– pirazolo[4,3–d]pirimidin–5–il)but–1–en–1– il)fenil)acrílico 397
- 150 *
-
Ácido (E)–3–(4–((E)–2–(3– (Carboximetoxi)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico
imagen101 345
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 151
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1H–indazol–5–il)–3–metilbut– 1–en–1–il)fenil)acrílico
imagen102 461
- 152 *
-
Ácido (E)–3–(4–((E)–1–(6–Hidroxipiridin–3–il)– 2–fenilbut–1–en–1–il)fenil)acrílico
imagen103 372
- 153
- Ácido (E)–3–(4–((E)–1–(1H–Imdazol–5–il)–2– (3–(trifluorometoxi)fenil)but–1–en–1– il)fenil)acrílico 479
- 154 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–3– metil–2–(4–metiltiofen–3–il)but–1–en–1– il)fenil)acrílico 429
- 155
-
Ácido (E)–3–(4–((E)–2–Ciclobutil–1–(1H– indazol–5–il)–2–fenilvinil)fenil)acrílico
imagen104 421
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 156 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]isotiazol–5– il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen105 412
- 157
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclobutilo–1–(1H–indazol–5– il)vinilfenil)acrílico 473
- 158
- Ácido (E)–3–(4–((E)–1–(3–Fluoro–1H– indazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 413
- 159 *
- Ácido (E)–3–(4–((E)–1–(2– Metilbenzo[d]biazol–5–il)–2–fenilbut–1–en–1– il)fenil)acrílico 426
- 160 *
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(4–(pirimidin–2–iloxi)fenil)but– 1–en–1–il)fenil)acrílico 507
16-04-2015 E14155086
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 161 *
-
Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(4–(pirazin–2–iloxi)fenil)but– 1–en–1–il)fenil)acrílico
imagen106 507
- 162 *
- Ácido (E)–3–(4–((E)–2–Ciclobutil–1–(1H– indazol–5–il)–2–(4–((5–(metilsulfonil)piridin– 2–il)oxi)fenil)vinil)fenil)acrílico 592
- 163 *
- Ácido (E)–3–(4–((E)–1–(7– Metoxibenzofuran–3–il)–2–fenilbut–1–en–1– il)fenil)acrílico No observado
- 164 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(7–metoxibenzofuran–3– il)but–1–en–1–il)fenil)acrílico
imagen107 477
- 165
- Ácido (E)–3–(4–((E)–2–Ciclobutil–1–(3– fluoro–1H–indazol–5–il)–2– fenilvinil)fenil)acrílico 439
16-04-2015
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 166
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(3–fluoro–1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico
imagen108 465
- 167
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclobutilo–1–(3–fluoro–1H– indazol–5–il)vinil)fenil)acrílico 491
- 168 *
-
Ácido (E)–3–(4–((E)–1–(Isoquinolin–7–il)–2– fenilbut–1–en–1–il)fenil)acrílico
imagen109 405
- 169 *
-
Ácido (E)–3–(4–((E)–1–(Benzofurin–2–il)–2– (2–cloro–4–Fluorofenil)but–1–en–1– il)fenil)acrílico
imagen110 447
- 170 *
-
Ácido (E)–3–(4–((E)–1(Benzofuran–3–il)–2– (2–cloro–4–Fluorofenil)but–1–en–1– il)fenil)acrílico
imagen111 447
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 171
-
3–(4–((E)–2–(4–Fluorofenil)–1–(1H–indazol– 5–il)but–1–en–1–il)fenil)acrilato de (E)–Etilo
imagen112 441
- 172 *
- 3–(4–((E)–1–(1H–indazol–6–il)–2–fenilbut–1– en–1–il)fenil)acrilato de (E)–Etilo 423
- 173
-
3–(4–((E)–1–(1H–Indazol–5–il)–2–(2– metoxifenil)but–1–en–1–il)fenil)acrilato de (E)–Etilo
imagen113 453
- 174
- 3–(4–((E)–1–(1H–Indazol–5–il)–2–(4– metoxifenil)but–1–en–1–il)fenil)acrilato de (E)–Etilo 453
- 175 *
- 3–(4–((E)–1–(1H–Indalol–4–il)–2–fenilbut–1– en–1–il)fenil)acrilato de (E)–Etilo 423
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 176
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)–2–metilacrílico
imagen114 409
- 177
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en1–il)–3–metilfenil)acrílico
imagen115 409
- 178
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–2–metilfenil)acrílico 409
- 179
- Ácido (E)–3–(4–((Z)–1–(1H–indazol–5–il)–2– fenilbut–1–en–1–il)–2–clorofenil)acrílico 429
- 180 *
-
Ácido (E)–3–(6–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)naftalen–2–il)acrílico
imagen116 445
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 181
-
Ácido (Z)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–on–1–il)fenil)–2–fluoroacrílico
imagen117 413
- 182
- Ácido (Z)–3–(4–((E)–1–(1H–1–Indazol–5–il)– 2–fenilbut–1–en–1–il)fenil)–2–cloroacrílico 429
- 183
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–3–Fluorofenil)acrílico
imagen118 413
- 184
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–2–flluorofenil)acrílico
imagen119 413
- 185
- Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–2– (trifluorometil)fenil)acrílico 463
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 186 *
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)tiofen–2–il)acrílico
imagen120 401
- 187
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–3–metoxifenil)acrílico
imagen121 425
- 188
-
Ácido (E)–3–(4–((Z)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)–2–metoxifenil)acrílico
imagen122 425
- 189 *
-
Ácido (E)–3–(5–((Z)–1–(1H–Indazol–5–il])–2– fenilbut–1–en–1–il)piridin–2–il)acrílico
imagen123 396
- 190
- Ácido (E)–2–(4–(1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenoxi)acético 399
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 191 *
-
(E)–5–(2–Fenil–1–(4–(2–(pirrolidin–1– il)etoxi)fenil)but–1–en–1–il)–1H–indazol
imagen124 438
- 192 *
- Ácido (E)–5–(1–(1H–Indazol–5–il)–2–fenilbut– 1–en–1–il)–2,3–dihidro–1H–indeno–2– carboxílico 409
- 193 *
- 3–(4–((E)–2–(2–cloro–4–Fluorofenil)–1–(1– (tetrahidro–2H–piran–2–il)–1H–indazol–5– il)but–1–en–1–il)fenil)acrilato de (E)–Etilo 475 [(M–THP+H)+H]+
- 194
- Clorhidrato de 3–(4–((E)–2–(2–cloro–4– fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrilato de (E)–Etilo 475
- 195
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 447
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 196
-
3–(4–((E)–2–(2,4–diclorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrilato de (E)–Etilo
imagen125 49
- 197
-
Ácido (E)–3(4–(E)–2–(2,4–Diclorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen126 463
- 198
- Ácido (E)–3(4((E)–2–(4–Cloro–2– (trifluorometil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 497
- 199
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclopropilo–1–(1H–indazol–5– il)vinil)fenil)acrílico
imagen127 459
- 200
- Ácido (E)–3–(4–((E)–2–(4–Fluoro–2– (trifluorometil)fenil)–1 –(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 481
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 201
-
Ácido (E)–3–(4–(1–(4–Fluoro–1H–indazol–5– il)–2–(4–fluoro–2–(trifluometil) fenil)butil)fenil)acrílico
imagen128 499
- 203
- Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)–1– (4–fluoro–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 481
- 203
- Ácido (E)–3–(4–((E)–2–(4–Cloro–2– (trifluorometil)fenil)–1–(4–fluoro–1H–indazol– 5–il)but–1–en–1–il)fenil)acrílico 515
- 204 *
- Ácido (E)–3–(4–((E)–2–(3–Cloropiridin–4–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 430
- 205
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–4–fluoro–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 465
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 206
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– metoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen129 459
- 207 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(trifluorometil)piridin–3–il)but–1–en–1– il)fenil)acrílico 464
- 208 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (1–metil–1H–pirazol–5–il)but–1–en–1– il)fenil)acrílico
imagen130 399
- 209
-
Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)–4– fluoro–1–(4–fluoro–1H–indazol–5–il)but–1–en– 1–il)fenil)acrílico
imagen131 499
- 210
- Ácido (E)–3–(4–((E)–2–Ciclopropilo–2–(2,4– diclorofenil)–1–(4–fluoro–1H–indazol–5– il)vinil)fenil)acrílico 493
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 211
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclopropilo–1–(4–fluoro–1H– indazol–5–il)vinil)fenil)acrílico
imagen132 477
- 212 *
- Ácido (E)–3–(4–((E)–2–(4–(Dimetilcarbamoil)– 2–Fluorofenil)–1–(1H–indazol–5–il)but–1–en– 1–il)fenil)acrílico 484
- 213 *
- Ácido (E)–3–(4–((E)–2–(2–Fluoro–4– (metilcarbamoil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 470
- 214 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metiltiofen–3–il)but–1–en–1–il)fenil)acrílico
imagen133 415
- 215
- Ácido (E)–3–(4–((E)–2–Ciclopropilo–2–(2,4– diclorofenil)–1–(1H–indazol–5– il)vinil)fenil)acrílico 475
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 216
-
Ácido (E)–3–(4–((E)–2–(4–Cloro–2– metilfenil)–3–ciclopropilo–1–(1H–indazol–5– il)vinil)fenil)acrílico
imagen134 455
- 217 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metilpiridin–3–il)but–1–en–1–il)fenil)acrílico
imagen135 410
- 218 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–metilpiridin–3–il)but–1–en–1–il)fenil)acrílico
imagen136 410
- 219 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (pirazin–2–il)but–1–en–1–il)fenil)acrílico 397
- 220 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (pirimidin–5–il)but–1–en–1–il)fenil)acrílico
imagen137 397
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 221 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (1–metil–1H–1,2,3–triazol–5–il)but–1–en–1– il)fenil)acrílico
imagen138 400
- 222 *
-
Ácido (E)–3–(4–((E)1–(1H–Indazol–5–il)–2– (2–(trifluorometil)piridin–3–il)but–1–en–1– il)fenil)acrílico
imagen139 464
- 223 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–metiltiofen–3–il)but–1–en–1–il)fenil)acrílico 415
- 224 *
- Ácido (E)–3–(4–((E)–1–(3–Cloropiridin–4–il)– 1–(4–fluoro–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 448
- 225 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (isotiazol–4–il)but–1–en–1–il)fenil)acrílico 402
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 226 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–metilpiridin–4–il)but–1–en–1–il)fenil)acrílico
imagen140 410
- 227 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (5–metiltiofen–2–il)but–1–en–1–il)fenil)acrílico 415
- 228
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metil–5–(metilsulfonil)fenil)but–1–en–1– il)fenil)acrílico
imagen141 487
- 229 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metiltiazol–5–il)but–1–en–1–il)fenil)acrílico
imagen142 416
- 230 *
- Ácido (E)–3–(4–((E)–2–(3–Cloropiridin–4–il)– 4–fluoro–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 448
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 231 *
-
Ácido (E)–3–(4–((E)–2–(3–Fluoropiridin–4–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen143 414
- 232 *
- Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)–1– (imidazo[1,2–a]piridin–6–il)but–1–en–1– il)fenil)acrílico 463
- 233 *
-
Ácido (E)–3–(4–((E)–2–(4–Fluoro–2– (trifluorometil)fenil)–1–(imidazo[1,2–a]piridin– 6–il)but–1–en–1–il)fenil)acrílico
imagen144 481
- 234
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il(–2– (4–metoxi–2–metilfenil)but–1–en–1– il)fenil)acrílico
imagen145 439
- 235
- Ácido (E)–3–(4–((E)–2–(2–Fluoro–4– metoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 443
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 236 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metoxipiridin–4–il)but–1–en–1– il)fenil)acrílico
imagen146 426
- 237
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–5– metoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen147 459
- 238
-
Ácido (E)–3–(4–((E)–2–(2–Fluoro–4– (metilsulfonil)fenil)–1–(1H–indazol–5–il)but–1– en–1–il)fenil)acrílico
imagen148 491
- 239
- Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)– 3,3,4,4,4–pentadeutero–1–(1H–indazol–5– il)but–1–en–1–il)fenil)acrílico 468
- 240 *
- Ácido (E)–3–(4–((E)–2–(Benzo[d][1,3]dioxol– 5–il)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 439
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 241 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–metiltiofen–2–il)but–1–en–il)fenil)acrílico
imagen149 415
- 242 *
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(4–metiltiofen–3–il)but–1–en– 1–il)fenil)acrílico 433
- 243
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(metilsulfonil)fenil)but–1–en–1– il)fenil)acrílico 473
- 244
-
Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)–1– (7–fluoro–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen150 481
- 245 *
-
Ácido (E)–3–(4–((E)–2–(3–Cloropiridin–4–il)– 1–(7–fluoro–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen151 448
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 246 *
-
Ácido (E)–3–(4–((E)–2–Fenil–1–(5H– pirolo[2,3–b]pirazin–2–il)but–1–en–1– il)fenil)acrílico
imagen152 396
- 247 *
- Ácido (E)–3–((E)–2–(Benzofuran–5–il)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 435
- 248
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–3– metoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen153 459
- 249
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pirrolidin–1–il)fenil)but–1–en–1– il)fenil)acrílico 464
- 250 *
- Ácido (E)–3–(4–((E)–2–(2,3– Dihidrobenzo[b][1,4]dioxin–6–il)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 453
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 251 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (1H–indazol–6–il)but–1–en–1–il)fenil)acrílico
imagen154 435
- 252
- Ácido (E)–3–(4–((E)–2–(3–(1H–Pirazol–1– il)fenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 461
- 253
- Ácido (E)–3–(4–((E)–2–(2,4–Diclorofenil)–1– (7–fluoro–1H–indol–5–il)but–1–en–1– il)fenil)acrílico 478
- 254
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(7–fluoro–1H–indom–5–il)but– 1–en–1–il)fenil)acrílico no observado
- 255 *
- Ácido (E)–3–(4–((E)–2–(Benzo[d]tiazol–5–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 452
- Compuesto
- Nombre Estructura LCMS [M+M]+
- 256 *
-
Ácido (E)–3–(4–((E)–2–(2,3– Dihidrobenzofuran–5–il)–1–(1H–indazol–5– il)but–1–en–1–il)fenil)acrílico
imagen155 437
- 257 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–4– metil–2–(4–metiltiofen–3–il)pent–1–en–1– il)fenil)acrílico 443
- 258 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (1–metil–1H–indazol–6–il)but–1–en–1– il)fenil)acrílico 449
- 259 *
- Ácido (E)–3–(4–((E)–2–(Benzo[d]tiazol–6–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 452
- 260 *
- Ácido (E)–3–(4–((E)–2–(Imidazo[1,2–a]piridin– 6–il)–1–(1H–indazol–5–y)but–1–en–1– il)fenil)acrílico 435
- Compuesto
- Nombre Estructura LCMS [M+M]+
- 261 *
-
Ácido (E)–3–(4–((E))–1–(1H–Indazol–5–il)–2– (3–fenoxifenil)but–1–en–1–il)fenil)acrílico
imagen156 487
- 262 *
-
Ácido (E)–3–(4–((E)–1–(1H–indazol–5–il)–2– (4–metil–3–oxo–3,4–dihidro–2H– benzo[b][1,4]oxazin–6–il)but–1–en–1– il)fenil)acrílico
imagen157 480
- 263 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–fenoxifenil)but–1–en–1–il)fenil)acrílico 487
- 264 *
-
Ácido (E)–3–(4–((E)–2–(4–(1H–Pyrazol–1– il)fenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen158 461
- 265 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–morfolinofenil)but–1–en–1–il)fenil)acrílico
imagen159 480
- Compuesto
- Nombre Estructura LCMS [M+M]+
- 266 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (quinoxalin–6–il)but–1–en–1–il)fenil)acrílico
imagen160 447
- 267 *
- Ácido (E)–3–(4–((E)–2–(2–Clorotiofen–3–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 435
- 268 *
-
Ácido (E)–3–(4–((E)–2–(Benzo[b]tiofen–2–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen161 451
- 269 *
- Ácido (E)–3–(4–((E)–2–(3–(4– Fluorofenoxi)fenil)–1–(1H–indazol–5–il)but–1– en–1–il)fenil)acrílico 505
- 270 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (5–metil–4,5,6,7–tetrahidrotieno[3,2–c]piridin– 2–il)but–1–en–1–il)fenil)acrílico 470
- Compuesto
- Nombre Estructura LCMS [M+M]+
- 271 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (5–feniltiofen–3–il)but–1–en–1–il)fenil)acrílico
imagen162 477
- 272*
-
Ácido (E)–3–(4–((E)–2–(Benzo[b]tiofen–5–il)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen163 451
- 273*
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metilbenzo[d]tiazol–5–il)but–1–en–1– il)fenil)acrílico 466
- 274*
- Ácido (E)–3–(4–((E)–2–(2,5–Dimetiltiofen–3– il)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 429
- 275*
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(2–cloro–4–Fluorofenil)but–1–en–1– il)fenil)acrílico 464
- Compuesto
- Nombre Estructura LCMS [M+M]+
- 276*
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(4–metiltiofen–3–il)but–1–en–1– il)fenil)acrílico
imagen164 432
- 277
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–3,3,4,4,4–pentadeutero–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 452
- 278*
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(2–cloro–4–Fluorofenil)–2– ciclobutilovinil)fenil)acrílico 490
- 279*
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–ciclobutilo–2–(4–metiltiofen–3– il)vinil)fenil)acrílico
imagen165 458
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 280 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(2–clorofenil)but–1–en–1–il)fenil)acrílico
imagen166 446
- 281 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(4–Fluorofenil)but–1–en–1–il)fenil)acrílico 430
- 282 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(4–fluoro–2–metilfenil)but–1–en–1– il)fenil)acrílico 444
- 283 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(o–toluil)but–1–en–1–il)fenil)acrílico 426
- 284 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(3–cloropiridin–4–il)but–1–en–1– il)fenil)acrílico 447
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 285 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il– 2–(3–cloropiridin–4–il)but–1–en–1– il)fenil)acrílico
imagen167 473
- 286 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–ciclobutilo–2–fenilvinil)fenil)acrílico 438
- 287 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1–oxoisoindolin–5–il)but–1– en–1–il)fenil)acrílico
imagen168 462
- 288
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(4–((trifluorometil)sulfonil)fenoxi)fenil)but– 1–en–1–il)fenil)acrílico 527
- 289 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(quinolin–7–il)but–1–en–1– il)fenil)acrílico 458
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 290 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(pirimidin–2–iloxifenil)but–1–en–1– il)fenil)acrílico
imagen169 489
- 291 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– fenoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen170 521
- 292 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(piridin–3–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen171 488
- 293 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(pirazin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico 489
- 294 *
-
Ácido (E)–3–(4–((E)–2–(4–Fluoro–3– fenoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen172 505
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 295 *
-
Ácido (E)–3–(4–((E)–2–(3–Fluoro–4– fenoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen173 505
- 296 *
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(4–(piridin–2–iloxi)fenil)but–1– en–1–il)fenil)acrílico 506
- 297 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–metil–5–fenoxifenil)but–1–en–1– il)fenil)acrílico 501
- 298 *
- Ácido (E)–3–(4–((E)–2–(2–Fluoro–3– fenoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 505
- 299 *
- Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(3–fenoxifenil)but–1–en–1–il)fenil)acrílico 504
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 300 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(3–(piridin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen174 505
- 301 *
-
Ácido (E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)– 2–(3–(pirazin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen175 506
- 302
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–((trifluorometil)sulfinil)fenil)but–1–en–1– il)fenil)acrílico
imagen176 511
- 303
-
Ácido (E)–3–(4–((E)–2–(3–Cianopiridin–4–il)– 1–(1H–indazolol–5–il)but–1–en–1– il)fenil)acrílico
imagen177 421
- 304 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(trifluorometil)piridin–4–il)but–1–en–1– il)fenil)acrílico 464
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 305 *
-
Ácido (E)–3–(4–((E)–2–(3–Cloropiridin–4–il)– 2–ciclobutilo–1–(1H–indazol–5– il)vinil)fenil)acrílico
imagen178 456
- 306 *
- Ácido (E)–3–(4–((E)–2–(3–Cloropiridin–4–il)– 1–(3–fluoro–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 448
- 307 *
- Ácido (E)–3–(4–((E)–1–(3–Cloropiridin–4–il)– 2–ciclobutilo–1–(3–fluoro–1H–indazol–5– il)vinil)fenil)acrílico 474
- 308
- Ácido (E)–3–(4–((E)–2–(4–Cloro–2– cianofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 454
- 309
- Ácido (E)–3–(4–((E)–(2–Ciano–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 438
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 310
-
Ácido (E)–3–(4–((E)–2–(2–Ciano–4– (trifluorometil)fenil)–1–(1H–indazol–5–il)but–1– en–1–il)fenil)acrílico
imagen179 488
- 311 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–2–ciclobutilo–1–(imidazo[1,2– a]piridin–6–il)vinil)fenil)acrílico 473
- 312 *
- Ácido (E)–3–(4–((E)–1–(3–Fluoro–1H– indazol–5–il)–2–(4–metiltiofen–3–il)but–1–en– 1–il)fenil)acrílico 433
- 313 *
- Ácido (E)–3–(4–((E)–2–Ciclobutil–1–(3–fluoro– 1H–indazol–5–il)–2–(4–metiltiofen–3– il)vinil)fenil)acrílico 459
- 314 *
- Ácido (E)–3–(4–((E)–2–(Benzo[d]isotiazol–5– il)–1–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 452
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 315 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(piridin–4–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen180 488
- 316 *
- Ácido (E)–3–(4–((E)–1–(1H–Indalol–5–il)2–(4– (piridin–2–iloxi)fenil)but–1–en–1–il)fenil)acrílico 488
- 317 *
- Ácido (E)–3–(4–((E)–2–(4–Bencilfenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrílico 485
- 318 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–metil–3–fenoxilfenil)but–1–en–1– il)fenil)acrílico
imagen181 501
- 319 *
- Ácido (E)–3–(4–((E)–1–(1H)–Indazol–5–il)–2– (2–metil–4–fenoxifenil)but–1–en–1– il)fenil)acrílico 501
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 320 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–metil–4–fenoxifenil)but–1–en–1– il)fenil)acrílico
imagen182 50]
- 321 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(3–(metilsulfonil)fenoxi)fenil)but–1–en–1– il)fenil)acrílico
imagen183 565
- 322
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– cianofenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 454
- 323
-
Ácido (E)–3–(4–((E)–2–(3–Ciano–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen184 434
- 324
- Ácido (E)–3–(4–((E)–2–(4–Ciano–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 434
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 325
-
Ácido (E)–3–(4–((E)–2–(5–Ciano–2– metilfenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen185 434
- 326
- Ácido (E)–3–(4–((E)–2–(2–Ciano–4– metoxifenil)–1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 450
- 327
- Ácido (E)–3–(4–((E)–2–(3– (Carboximetil)fenil)–1–(1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 453
- 328
- Ácido (E)–3–(4–((E)–2–(4–(Carboximetilfenil)– 1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 453
- 329 *
-
5–((E)–1–(4–((S)–2–((R)–3–Metilpirrolidin–1– il)propoxi)fenil)–2–fenilbut–1–en–1–il)–1H– indazol
imagen186 466
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 330 *
-
5–((E)–2–(2–Clorofenil)–1–(4–((S)–2–((R)–3– metilpirrolidin–1–il)propoxi)fenil)but–1–en–1– il)–1H–indazol
imagen187 500
- 331 *
-
5–((E)–2–(3–Cloropiridin–4–il)–1–(4–((S)–2– ((R)–3–metilpirrolidin–1–il)propoxi)fenil)but– 1–en–1–il)–1H–indazol
imagen188 501
- 332 *
- Ácido (E)–1–(4–(2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1– il)fenoxi)ciclopropanocarboxílico 477
- 333 *
- (E)–5–(4–(2–(2–Cloro–4–Fluorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)isoxazol–3–ol 460
- 334 *
- (E)–3–(4–(2–(2–Cloro–4–Fluorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)isoxazol–5–ol 460
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 335
-
Ácido (E)–3–(4–((E)–2–(3–Hidroxifenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen189 411
- 336
- Ácido (E)–3–(4–((E)–2–(2–Hidroxifenil)–1– (1H)–indazol–5–il)but–1–en–1–il)fenil)acrílico 411
- 337
-
Ácido (E)–3–(4–((E)–2–(4–Hidroxifenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen190 411
- 338
- Ácido (E)–3–(4–(1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)propanoico 397
- 339 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5– metoxietoxi)fenil)but–1–en–1–il)fenil)acrílico 469
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 340 *
-
Ácido (E)–3–(4–(E)–1–(1H–Indazol–5–il)–2– (4–(3–metoxipropoxi)fenil)but–1–en–1– il)fenil)acrílico
imagen191 483
- 341 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(2–metoxietoxi)fenil)but–1–en–1– il)fenil)acrílico 469
- 342 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(3–metoxipropoxi)fenil)but–1–en–1– il)fenil)acrílico
imagen192 483
- 343 *
-
Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(3–((1–metilpiperidin–4– il)oxi)fenil)but–1–en–1–il)fenil)acrílico
imagen193 526
- 344 *
-
Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–(3–((tetrahidro–2H–piran–4– il)oxi)fenil)but–1–en–1–il)fenil)acrílico
imagen194 513
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 345
-
Ácido (E)–3–(4–((E)–2–(3– (Ciclohexiloxi)fenil)–1–(4–fluoro–1H–indazol– 5–il)but–1–en–1–il)fenil)acrílico
imagen195 511
- 346
-
Ácido (E)–3–(4–((E)–2–(3–Butoxifenil–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen196 467
- 347 *
- Ácido (E)–3–(4–((E)–2–(3– (Carboximetoxi)fenil)–1–(1H–indazol–5– il)but–1–en–1–il)fenil)acrílico 469
- 348 *
- Ácido (E)–3–(4–((E)–2–(4– (Carboximetoxi)fenil)–1–(1H–indazol–5– il)but–1–en–1–il)fenil)acrílico 469
- 349
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pentiloxi)fenil)but–1–en–1–il)fenil)acrílico
imagen197 481
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 350
-
Ácido (E)–3–(4–((E)–2–(3–(Hexiloxi)fenil)– 1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen198 495
- 351 *
- Ácido 4–(3–((E)–1–(4–((E)–2– Carboxivinil)fenil)–1–(1H–indazol–5–il)but– 1–en–2–il)fenoxi)butanoico 497
- 352 *
-
Ácido 5–(3–((E)–1–(4–((E)–2– Carboxivinil)fenil)–1–(1H–indazol–5–il)but– 1–en–2–il)fenoxi)pentanoico
imagen199 511
- 353 *
- Ácido 4–(4–((E)–1–(4–((E)–2– Carboxivinil)fenil)–1–(1H–indazol–5–il)but– 1–en–2–il)fenoxi)butanoico 497
- 354 *
-
Ácido 5–(4–((E)–1–(4–((E)–2– Carboxivinil)fenil)–1–(1H–indazol–5–il)but– 1–en–2–il)fenoxi)pentanoico
imagen200 511
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 355
-
Ácido (E)–3–(4–((E)–2–(4–Butoxifenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico
imagen201 467
- 356
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(pentiloxi)fenil)but–1–en–1–il)fenil)acrílico 481
- 357
- Ácido (E)–3–(4–((E)–1–(4–(Hexiloxi)fenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 495
- 358 *
- Ácido (E)–3–(4–((E)–2–(3–(Benciloxi)fenil)– 1–(1H–indazol–5–il)but–1–en–1– il)fenil)acrílico 501
- 359 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–3–ilmetoxi)fenil)but–1–en–1– il)fenil)acrílico 502
- Compuesto
- Nombre Estructura L–CMS [M+H]+
- 360 *
-
Ácido (E)–3–(4–((E)–2–(4–(2– Hidroxietoxi)fenil)–1–(1H–indazol–5–il)but–1– en–1–il)fenil)acrílico
imagen202 455
- 361
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (2–(metilsulfonil)fenil)but–1–en–1– il)fenil)acrílico 473
- 362 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen203 488
- 363 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pirimidin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico 489
- 364
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pirimidin–4–iloxi)fenil)but–1–en–1 il)fenil)acrílico 489
- Compuesto
- Nombre Estructura L–CMS [M+H]+
- 365 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–3–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen204 488
- 366 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–4–iloxi)fenil)but–1–en–1– il)fenil)acrílico 488
- 367 *
- Ácido (E)–3–(4–((E)–2–(3–(2– Fluorofenoxi)fenil)–1–(1H)–indazol–5–il)but–1– en–1–il)fenil)acrílico 505
- 368 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(o–toliloxi)fenil)but–1–en–1–il)fenil)acrílico
imagen205 501
- 369 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pirimidin–5–iloxi)fenil)but–1–en–1– il)fenil)acrílico 489
- Compuesto
- Nombre Estructura L–CMS [M+H]+
- 370 *
-
Ácido (E)–3–(4–((E)–]–1–(1H–Indazol–5–il)– 2–(3–(tiazol–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico
imagen206 494
- 371 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(pirazin–2–iloxi)fenil)but–1–en–1– il)fenil)acrílico 489
- 372 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–((3–(trifluorometil)piridin–4–il)oxi)fenil)but– 1–en–1–il)fenil)acrílico 556
- 373 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(4–(metilsulfonil)fenoxi)fenil)but–1–en–1– il)fenil)acrílico 565
- 374 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(2–(metilsulfonil)fenoxi)fenil)but–1–en–1– en–il)fenil)acrílico
imagen207 565
- Compuesto
- Nombre Estructura L–CMS [M+H]+
- 375 *
-
Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(3–(piridin–2–iloxi)fenil)but–1– en–1–il)fenil)acrílico
imagen208 506
- 376 *
-
Ácido (E)–3–(4–((E))–1–(4–fluoro–1H– indazol–5–il)–2–(3–(pirimidin–2–iloxi)fenil)but– 1–en–1–il)fenil)acrílico
imagen209 507
- 377 *
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(3–(pirazin–2–iloxi)fenil)but– 1–en–1–il)fenil)acrílico 507
- 378 *
- Ácido (E)–3–(4–((E)–1–(4–Fluoro–1H– indazol–5–il)–2–(3–((6–(metilsulfonil)piridin–3– il)oxi)fenil)but–1–en–1–il)fenil)acrílico 584
- 379 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–((5–(metilsulfonil)piridin–2–il)oxi)fenil)but– 1–en–1–il)fenil)acrílico 566
- Compuesto
- Nombre Estructura L–CMS [M+H]+
- 380 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–((6–(metilsulfonil)piridin–3–il)oxi)fenil)but– 1–en–1–il)fenil)acrílico
imagen210 566
- 381 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–((5–(trifluorometil)piridin–2–il)oxi)fenil)but– 1–en–1–il)fenil)acrílico 556
- 382 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–((6–metilpiridin–3–il)oxi)fenil)but–1–en–1– il)fenil)acrílico
imagen211 502
- 383 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(pirimidin–5–il)fenil)but–1–en–1– il)fenil)acrílico
imagen212 473
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 384 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5 il)–2– (4–(1–metil–1H–pirazol–4–il)fenil)but–1–en– 1–il)fenil)acrílico
imagen213 475
- 385 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(piridin–2–il)fenil)but–1–en–1– il)fenil)acrílico 472
- 386 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(tiofen–3–il)fenil)but–1–en–1– il)fenil)acrílico 477
- 387 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(tiazol–2–il)fenil)but–1–en–1–il)fenil)acrílico 478
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 388 *
-
Ácido (E)–3–(4–((E)–(1H–Indazol–5–il)–2–(4– (thiazol]–4–ilfenil)but–1–en–1–il)fenil)acrílico
imagen214 478
- 389 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(pirazin–2–il)fenil)but–1–en–1– il)fenil)acrílico
imagen215 473
- 390 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–2–il)fenil)but–1–en–1– il)fenil)acrílico 472
- 391 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5 il)–2– (3–(tiazol–2–il)fenil)but–1–en–1–il)fenil)acrílico 478
- 392 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(tiazol–4–il)fenil)but–1–en–1–il)fenil)acrílico 478
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 393 *
-
Ácido (E)–3–(4–((E)–1–1H–Indazol–5–il)–2– (3–(piridin–3–il)fenil)but–1–en–1– il)fenil)acrílico
imagen216 472
- 394 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (3–(piridin–4–il)fenil)but–1–en–1– il)(fenil)acrílico 472
- 395 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(isotiazol–4–il]fenil)but–1–en–1– il)fenil)acrílico 478
- 396 *
-
Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(metil(fenil)amino)fenil)but–1–en–1– il)fenil)acrílico
imagen217 500
- 397 *
- Ácido (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– (4–(fenilamino)fenil)but–1–en–1–ilfenil)acrílico 486
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 398 *
-
Ácido (E)–3–(4–((E)–2–(2–Clorofenil)–1–(– metil–1H–indazol–5–il)but–1–en–1– il)fenil)acrílico
imagen218 443
- 399 *
- Ácido (E)–3–(4–((E)–2–Ciclobutil–1–(1–metil– 1H–indazol–5–il)–2–fenilvinil)fenil)acrílico 435
- 400 *
- Ácido (E)–3–(4–((E)–2–(2–(2–Cloro–4– Fluorofenil)–1–(1–metil–1H–indazol–5–il)but– 1–en–1–il)fenil)acrílico 461
- 401 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1–(difluorometil)–1H–indazol– 5–il)but–1–en–1–il)fenil)acrílico
imagen219 497
- 402 *
- Ácido (E)–3–(4–((E)–2–Cloro–4–Fluorofenil)– 1–(2–(difluorometil)–2H–indazol–5–il)but–1– en–1–il)fenil)acrílico 497
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 403 *
-
Ácido (E)–3–(4–((E)–1–(1–Acetil–1H–indazol– 5–il)–2–(2–cloro–4–Fluorofenil)but–1–en–1– il)fenil)acrílico
imagen220 489
- 404 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1–isobutyril–1H–indazol–5– il)but–1–en–1–il)fenil)acrílico
imagen221 517
- 405 *
- Ácido (E)–3–(4–((E)–2–(2–(Cloro–4– Fluorofenil)–1–(1–pivaloil–1H–indazol–5– il)but–1–en–1–il)fenil)acrílico 531
- 406 *
-
Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1–(etoxicarbonil)–1H–indazol– 5–il)but–1–en–1–il)fenil)acrílico
imagen222 519
- 407 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(1–(tetrahidro–2H–piran–2–il)– 1H–indazol–5–il)but–1–en–1–il)fenil)acrílico 447 [(M–THP+H )+H]+
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 408 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)–N– (metilsulfonil)acrilamida
imagen223 524
- 409 *
- (E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)–N– (propilsulfonil)acrilamida 552
- 410 *
-
(E)–3–(4–((E)–1–(2–Cloro–4–flurofenil)–1– (1H–indazol–5–il)but–1–en–1–fenil)–N– (pentilsulfonil)acrilamida
imagen224 580
- 411 *
-
(E)–3–(4–((E)–2–Ciclobutil–1–(1–metil–1H– indazol–5–il)–2–fenilvinil)fenil)–N– metilacrilamida
imagen225 448
- 412 *
- (E)–3–(4–((E)–2–Ciclobutil–1–(1H–indazol– 5–il)–2–fenilvinil)fenil)fenil)–N– metilacrilamida 434
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 413 *
-
(E)–3–(4–((E)–2–Ciclobutil–1–(3–fluoro–1H– indazol–5–il)–2–fenil)vinil)fenil)–N– ciclopropiloacrilamida
imagen226 478
- 414 *
- (E)–3–(4–((E)–2–Ciclobutil–1–(3–fluoro–1H– indazol–5–il)–2–fenilvinil)fenil)–N–(2– hidroxietil)acrilamida 482
- 415 *
-
(E)–3–(4–((E)–2–Ciclobutil–1–(3–fluoro–1H– indazol–5–il)–2–fenilvinil)fenil–N–(2,2,2,– trifluoroetil)acrilamida
imagen227 520
- 416 *
-
(E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)–2–(2– cloro–4–Fluorofenil)but–1–en–1–il)fenil)–N– (metilsulfonil)acrilamida
imagen228 541
- 417 *
- (E)–3–(4–((E)–2–Cloro–4–Fluorofenil)–1–(1H– indazol–5–il)but–1–en–1–il)fenil)acrilamida 446
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 418 *
-
(E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)–N–hidroxiacrilamida
imagen229 410
- 419 *
- (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)–N–isopropilacrilamida 436
- 420 *
- (E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)–N– metilacrilamida 460
- 421 *
- (E)–3–(4–((E)–2–(2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)–N– metoxiacrilamida 476
- 422 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)–N– metoxi–N–metilacrilamida
imagen230 490
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 423 *
-
(E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)–N– (metilsulfonil)acrilamida
imagen231 472
- 424 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1–metil–1H–indazol–5–il)but–1–en–1– il)fenil)–N–(metilsulfonil)acrilamida
imagen232 538
- 425 *
- (E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)fenil)–N– (2H–tetrazol–5–il)acrilamida 514
- 426 *
-
(E)–3–(4–((E)–1–(Benzo[d]tiazol–5–il)–2– fenilbut–1–co–1–il)fenil)acrilamida
imagen233 41
- 427 *
- (E)–3–[4–((E)–1–(Benzo[d]tiazol–5–il)–2– fenilbut–1–en–1–il)fenil)–N–metilacrilamida 425
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 428 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)– N–(fenilsulfonil)acrilamida
imagen234 586
- 429 *
-
(E)–N–(Bencilsulfonil)–3–(4–((E)–2–(2– cloro–4–Fluorofenil)–1–(1H–indazol–5– il)but–1–en–1–il)fenil)acrilamida
imagen235 600
- 430 *
- (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil–N–(tiazol–2– il)acrilamida 477
- 431 *
- (E)–3–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)–N– ciclopentiloacrilamida 462
- 432 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)– N–(piridin–2–ilsulfonil)acrilamida
imagen236 587
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 433 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)– N–(piridin–3–ilsulfonil)acrilamida
imagen237 587
- 434 *
-
(E)–3–(4–((E)–2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)fenil)– N–(piridin–4–ilsulfonil)acrilamida
imagen238 587
- 435 *
-
3–((E)–4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)estiril)–1,2,4–oxadiazol– 5(4H)–ona
imagen239 435
- 436 *
- 3–((E)–4–((E)–1–(Benzo[d]tiazol–5–il)–2– (2–cloro–4–Fluorofenil)but–1–en–1– il)estiril)–1,2,4–oxadiazol–5(4H)–ona 504
- 437 *
- 3–((E)–4–((E)–2–(2–Cloro–4–Fluorofenil)– 1–(1H–indazol–5–il)but–1–en–1–il)estiril)– 1,2,4. oxadiazol–5(4H)–ona 487
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 438 *
-
3–((E)–4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)estiril)–1–,2,4–tiadiazol– 5(4H)–ona
imagen240 451
- 439 *
- 3–((E)–4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)estiril)–1,2,4– tiadiazol–5(4H)–ona 503
- 440 *
- 3–((E)–4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)estiril)–1,2,4–oxadiazol– 5(4H)–tiona 451
- 441 *
- 3–((E)–4–((E)–2–(2–Cloro–4–Fluorofenil)–1– (1H–indazol–5–il)but–1–en–1–il)estiril)–1,2,4– oxadiazol–5(4H)–tiona 503
- 442 *
- 5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–fenilbut–1–en–1–il)–1H– indazol 419
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 443 *
-
5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–(2–clorofenil)but–1–en–1–il)– 1H–indazol
imagen241 453
- 444 *
-
5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–fenilbut–1–en–1– il)benzo[d]tiazol
imagen242 436
- 445 *
- 5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–(2–cloro–4–Fluorofenil)but–1– en–1–il)benzo[d]tiazol 488
- 446 *
- 5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–(3–cloropiridin–4–il)but–1–en– 1–il)benzo[d]tiazol 471
- 447 *
-
5–((E)–1–(4–((E)–2–(2H–Tetrazol–5– il)vinil)fenil)–2–(4–metiltiofen–3–il)but–1–en– 1–il)benzo[d]tiazol
imagen243 456
- Compuesto
- Nombre Estructura LCMS [M+H]+
- 448 *
-
5–((E)–1–((E)–2–(2H–Tetrazol–5–il)vinil)fenil)– 2–ciclobutilo–2–(4–metiltiofen–3– il)vinil)benzo[d]tiazol
imagen244 482
- 449
- Ácido (E)–6–(1–(1H–Indazol–5–il)–2–fenilbut– 1–en–1–il)–2–naftoico 419
- 450 *
- Ácido (E)–3–(4–((E)–2–(2–Cloro–4– Fluorofenil)–1–(7–hidroxibenzofuran–3–il)but– 1–en–1–il)fenil)acrílico 463
- 451 *
-
Ácido (E)–3–(4–((E)–1–(7–Hidroxibenzofuran– 3–il)–2–fenilbut–1–en–1–il)fenil)acrílico
imagen245 411
- 452 *
- (E)–2–(4–((E)–1–(1H–Indazol–5–il)–2– fenilbut–1–en–1–il)fenil)etanosulfonamida 430
Un matraz de fondo redondo de 200 mL equipado con una barra agitadora magnética, un septum de goma y entrada de N2 se cargó con 5–etinil–1– (tetrahidro–2H–piran–2–il) –1H–benzo [d] [1,2,3]triazol (2.5 g, 11 mmol) y THF anhidro (110 mL). Esta solución se enfrió entonces hasta 0 ºC en un baño de hielo. Entonces, se agregó una solución de LiHMDS (27 mL, THF 5 1M, 27 mmol) gota a gota durante 15 minutos. La mezcla resultante se agitó durante 1 h a 0 ºC. A esta mezcla a 0 ºC, se agregó yodoetano (4.4 mL, 55 mmol) gota a gota durante 5 minutos. La mezcla se calentó gradualmente hasta temperatura ambiente, se agitó durante 1 h, y luego se calentó a reflujo durante la noche. La reacción se monitorizó por LCMS. Al terminar, la mezcla de reacción se enfrió hasta temperatura ambiente, se detuvo con agua (100 mL), y se extrajo con acetato de etilo (2x100 mL). Las fases orgánicas combinadas se lavaron con agua (100 mL), se lavaron con salmuera (50 10 mL), se secaron sobre sulfato de sodio, se filtraron, y se concentraron para dar el producto crudo. Este material crudo se purificó sobre una columna de sílica gel eluida con 5% de acetato de etilo en hexanos produciendo el compuesto del título en forma de un aceite de color amarillo pálido (1.6g). 1H RMN (300 MHz, DMSO–d6): δ 7.92 (s, 1H), 7.85 (dd, 1H), 7.33 (dd, 1H), 6.01 (dd, 1H), 3.86–3.80 (m, 1H), 3.75–3.64 (m, 1H), 2.45–2.36 (m, 3H), 2.08–1.91 (m, 2H), 1.74–1.62 (m, 1H), 1.58–
15 Los Intermediarios de la Tabla 2 se prepararon a partir de materiales de partida conocidos o comerciales siguiendo los procedimientos delineados para los Intermediarios 1–4.
- Intermediario 5
- 6–(But–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
- Intermediario 6
- 4–(But–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
- Intermediario 7
-
1–(Tetrahidro–2H–piran–2–il)–5–(4,4,4–trideuterobut–1–in– 1–il)–1H–indazol
imagen278
- Intermediario 8
-
5–(But–1–in–1–il)–7–cloro–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
imagen279
- Intermediario 9
- 5–(But–1–in–1–il)–7–metil–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
- Intermediario 10
- 5–(But–1–in–1–il)–3–metil–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
- Intermediario 11
-
5–(But–1–in–1–il)–3–cloro–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
imagen280
- Intermediario 12
- 5–(Prop–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H– indazol
- Intermediario 13
-
5–(Pent–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H– indazol
imagen281
- Intermediario 14
- 5–(Perdeuterobut–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
Ejemplo 5: Preparación de 5–(But–1–in–1–il)–4–metil–1–(tetrahidro–2H–piran–2–il)–1H–indazol (Intermediario 15)
Etapa 1: 4–Metil–1–(tetrahidro–2H–piran–2–il)–5–((trimetilsilil)etinil)–1H–indazol
Una mezcla de 5–bromo–4–metil–1– (tetrahidro–2H–piran–2–il) –1H–indazol (915 mg, 3.10 mmol; preparada a partir de 5– bromo–4–metil–1H–indazol siguiendo el procedimiento delineado para el Intermediario 1), yoduro de cobre (72 mg, 0,38 mmol), tetracloropaladato de sodio (55 mg, 0.19 mmol), 2–(di–tert–butilfosfino)–1–fenil–1H–indol (128 mg, 0.379 mmol ), y TMEDA: H2O (9:1, 10 mL) se desgasificó con tres ciclos de vacío/nitrógeno. Se agregó etiniltrimetilsilano a la reacción, y la 10 mezcla se calentó hasta 80 ºC durante 90 min y luego se enfrió hasta temperatura ambiente. La mezcla de reacción se filtró a través de Celita y la Celita se lavó con acetato de etilo (100 mL). El filtrado se lavó (solución saturada de NaHCO3, 2 x 50 mL), se secó (Na2SO4), y se concentró bajo presión reducida. El material crudo se purificó sobre una columna de sílica gel
En un tubo de alta presión, una mezcla de 5–bromo–4–fluoro–1– (tetrahidro–2H–piran–2–il)–H–indazol (8.0 g, 26.8 mmol; Intermediario 21), PdCl2(PPh)3)2 (3.7 g, 5.35 mmol), CuI (1.0 g, 5.35 mmol) y trietilamina (30 mL) se desoxigenó con tres ciclos de vacío/nitrógeno. Se agregó etinilciclopropano (8.9 g, 134 mmol) bajo atmósfera de N2. El tubo se selló y la mezcla de reacción se calentó a 120 ºC durante 63 horas. Al terminar, la mezcla de reacción se diluyó con acetato de etilo y se filtró 5 a través de Celita. El filtrado se concentró in vacuo y el residuo se purificó mediante cromatografía de columna sobre sílica gel (0~10% de acetato de etilo en éter de petróleo) produciendo el compuesto del título (4.3 g). 1H RMN (400MHz, DMSO– d6): δ 8.25 (s, 1H), 7.55 (d, 1H), 7.40 (dd, 1H), 5.88 (dd, 1H), 3.88–3.85 (m, 1H), 3.76–3.73 (m, 2H), 2.43–2.33 (m, 1H), 2.05–
Los compuestos Intermediarios en la Tabla 4 se prepararon a partir del Intermediario 1 (o el isómero 4–bromo) siguiendo los 10 procedimientos delineados para los Intermediarios 17–20, 22.
Tabla 4.
- Intermediario 23
- 4–(Ciclopropiloetinil)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
- Intermediario 24
-
5–(Ciclopentiloetinil)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
imagen287
- Intermediario 25
- 5–(Ciclohexiloetinil)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
- Intermediario 26
-
5–(3–Metilbut–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
imagen288
- Intermediario 27
- 5–(Hex–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H–indazol
- Intermediario 28
- 5–(3–Ciclopentiloprop–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)– 1H–indazol
Ejemplo 12: Preparación de 5–(4–Clorobut–1–in–1–il)–1–(tetrahidro–2H–piran–2–il)–1H–indazol (Intermediario 29)
mezcla se agitó a temperatura ambiente durante la noche, y luego se agregó ácido fenil borónico adicional (186, 1.53 mmol). La reacción se agitó a temperatura ambiente durante 7 horas adicionales y se filtró a través de Celita con diclorometano. El filtrado se concentró y se purificó por cromatografía en sílica gel (100% de hexanos) para dar 1–bromo–2–cloro–4– fenoxibenceno (90 mg) como un líquido transparente. 1H RMN (400 MHz, DMSO–d6): δ 7.75 (d, 1H), 7.42–7.47 (m, 2H),
Los compuestos Intermediarios de la Tabla 9 se prepararon siguiendo el procedimiento delineado para el Intermediario 65.
Tabla 9.
- Intermediario 66
- 4–Bromo–1–fluoro–2–fenoxibenceno
- Intermediario 67
- 4–Bromo–2–fluoro–1–fenoxibenceno
- Intermediario 68
- 2–Bromo–1–metil–4–fenoxibenceno
- Intermediario 69
- 1–Bromo–2–fluoro–3–fenoxibenceno
- Intermediario 70
- 4–Bromo–1–metil–2–fenoxibenceno
- Intermediario 71
- 1–Bromo–2–metil–4–fenoxibenceno
- Intermediario 72
- 4–Bromo–2–metil–1–fenoxibenceno
- Intermediario 73
- (1–Yodo–3–(3– (metilsulfonil)fenoxi)benceno
Ejemplo 42: Preparación de 2–Bromo–5–metil–4,5,6,7–tetrahidrotieno[3,2–c]piridina (Intermediario 74)
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 1
- A + A ++
- 2
- A ++ A ++
- 3
- A ++ A ++
- 4
- A ++ A ++
- 5
- B ++ B ++
- 6
- A ++ A ++
- 7
- A ++ A ++
- 8
- B ++ A ++
- 9
- A ++ A ++
- 10
- B ++ A ++
- 11
- A ++ A ++
- 12
- A ++ A ++
- 13
- A ++ A ++
- 14
- A ++ A ++
- 15
- A ++ A ++
- 16
- A ++ A ++
- 17
- A ++ A ++
- 18
- A ++ A ++
- 19
- A ++ A ++
- 20
- A ++ A ++
- 21
- A ++ A ++
- 22
- A ++ A ++
- 23
- A ++ A ++
- 24
- A ++ A ++
- 25
- B ++ B ++
- 26
- A ++ A ++
- 27
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 28
- B ++ B ++
- 29
- A ++ A ++
- 30
- A ++ A ++
- 31
- A ++ A ++
- 32
- A ++ A ++
- 33
- A ++ A ++
- 34
- A ++ A ++
- 35
- A ++ A ++
- 36
- A ++ A ++
- 37
- A ++ A ++
- 38
- A ++ A ++
- 39
- A ++ A ++
- 40
- A ++ A ++
- 41
- A ++ A ++
- 42
- A ++ A ++
- 43
- A ++ A ++
- 44
- A ++ A ++
- 45
- A ++ A ++
- 46
- A ++ A ++
- 47
- A ++ A ++
- 48
- A ++ A ++
- 49
- B ++ B ++
- 50
- A ++ A ++
- 51
- B ++ B ++
- 52
- B ++ B ++
- 53
- A ++ A ++
- 54
- A ++ A ++
- 55
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 56
- B ++ A ++
- 57
- A ++ A ++
- 58
- A ++ A ++
- 59
- B + B ++
- 60
- A ++ A ++
- 61
- A ++ A ++
- 62
- B ++ B ++
- 63
- A ++ A ++
- 64
- A ++ A ++
- 65
- A ++ A ++
- 66
- A ++ A ++
- 67
- B ++ B ++
- 68
- B ++ B ++
- 69
- A ++ A ++
- 70
- A ++ A ++
- 71
- A ++ A ++
- 72
- A ++ A ++
- 73
- A ++ A ++
- 74
- A ++ A ++
- 75
- B ++ B ++
- 76
- A ++ A ++
- 77
- A ++ A ++
- 78
- A ++ A ++
- 79
- A ++ A ++
- 80
- A ++ A ++
- 81
- B ++ B ++
- 82
- A ++ A ++
- 83
- B ++ B ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 84
- A ++ A ++
- 85
- A ++ A ++
- 86
- A ++ A ++
- 87
- A ++ A ++
- 88
- B ++ B ++
- 89
- A ++ A ++
- 90
- B ++ B ++
- 91
- A ++ A ++
- 92
- A ++ A ++
- 93
- A ++ A ++
- 94
- A ++ A ++
- 95
- A ++ A ++
- 96
- A ++ A ++
- 97
- A ++ B ++
- 98
- A ++ A ++
- 99
- A ++ A ++
- 100
- B ++ B ++
- 101
- B ++ B ++
- 102
- B + B ++
- 103
- B ++ B ++
- 104
- B ++ B ++
- 105
- B ++ B ++
- 106
- A ++ A ++
- 107
- B ++ B ++
- 108
- A ++ A ++
- 109
- A ++ A ++
- 110
- A ++ A ++
- 111
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 112
- A ++ A ++
- 113
- A ++ A ++
- 114
- A ++ A ++
- 115
- A ++ A ++
- 116
- A ++ A ++
- 117
- A ++ A ++
- 118
- B ++ B ++
- 119
- A ++ A ++
- 120
- A ++ A ++
- 121
- A ++ A ++
- 122
- B ++ B ++
- 123
- B ++ A ++
- 124
- B + B ++
- 125
- B ++ B ++
- 126
- B ++ A ++
- 127
- B + B +
- 128
- B ++ B ++
- 129
- B ++ A ++
- 130
- B ++ B ++
- 131
- B ++ B ++
- 131
- B + B +
- 133
- B ++ B ++
- 134
- B + B +
- 135
- A + B ++
- 136
- B + B ++
- 137
- B + B ++
- 138
- B + B ++
- 139
- B ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 140
- B ++ A ++
- 141
- A ++ A ++
- 142
- A ++ A ++
- 143
- B ++ B ++
- 144
- B ++ B ++
- 145
- B ++ B ++
- 146
- B ++ B ++
- 147
- A ++ A ++
- 148
- B ++ B ++
- 149
- B + B ++
- 150
- B + B ++
- 151
- A ++ A ++
- 152
- B + B ++
- 153
- A ++ A ++
- 154
- A ++ A ++
- 155
- A ++ A ++
- 156
- B ++ B ++
- 157
- A ++ A ++
- 158
- A ++ A ++
- 159
- B ++ B ++
- 160
- A ++ A ++
- 161
- A ++ A ++
- 162
- A ++ A ++
- 163
- A ++ A ++
- 164
- A ++ A ++
- 165
- A ++ A ++
- 166
- A ++ A ++
- 167
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 168
- B ++ B ++
- 169
- A ++ A ++
- 170
- A ++ A ++
- 171
- A + A ++
- 172
- A + B ++
- 173
- A +
- 174
- A +
- 175
- A + A ++
- 176
- A ++ A ++
- 177
- A ++ A ++
- 178
- A ++ A ++
- 179
- A ++ A ++
- 180
- A ++ A ++
- 181
- B ++ A ++
- 182
- B ++ A ++
- 183
- A ++ A ++
- 184
- A ++ A ++
- 185
- B ++ A ++
- 186
- B + B ++
- 187
- A ++ A ++
- 188
- A ++ A ++
- 189
- B ++ B ++
- 190
- B ++ B ++
- 191
- A ++ A ++
- 192
- B ++ B ++
- 193
- A + B ++
- 194
- A + A ++
- 195
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 196
- A + A ++
- 197
- A ++ A ++
- 198
- A ++ A ++
- 199
- A ++ A ++
- 200
- A ++ A ++
- 201
- A ++ A ++
- 202
- A ++ A ++
- 203
- A ++ A ++
- 204
- A ++ A ++
- 205
- A ++ A ++
- 206
- A ++ A ++
- 207
- A ++ A ++
- 208
- B + B ++
- 209
- A ++ A ++
- 210
- A ++ A ++
- 211
- A ++ A ++
- 212
- B ++ B ++
- 213
- B + B ++
- 214
- A ++ A ++
- 215
- A ++ A ++
- 216
- A ++ A ++
- 217
- B ++ B ++
- 218
- B ++ B ++
- 219
- B ++ B ++
- 220
- B + B +
- 221
- B + B +
- 222
- A ++ A ++
- 223
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 224
- A ++ A ++
- 225
- B ++ B ++
- 226
- A ++ A ++
- 227
- A ++ A ++
- 228
- B + B +
- 229
- B ++ B ++
- 230
- A ++ A ++
- 231
- A ++ A ++
- 232
- A ++ A ++
- 233
- A ++ A ++
- 234
- A ++ A ++
- 235
- A ++ A ++
- 236
- A ++ A ++
- 237
- A ++ A ++
- 238
- B ++ B ++
- 239
- A ++ A ++
- 240
- A ++ A ++
- 241
- A ++ A ++
- 242
- A ++ A ++
- 243
- B + B ++
- 244
- A ++ A ++
- 245
- A ++ A ++
- 246
- B + B ++
- 247
- A ++ A ++
- 248
- A ++ A ++
- 249
- B ++ A ++
- 250
- A ++ A ++
- 251
- B ++ B ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 252
- B ++ A ++
- 253
- A ++ A ++
- 254
- A ++ A ++
- 255
- A ++ A ++
- 256
- A ++ A ++
- 257
- A ++ A ++
- 258
- B ++ A ++
- 259
- A ++ A ++
- 260
- B + B +
- 261
- A ++ A ++
- 262
- B ++ B ++
- 263
- A ++ A ++
- 264
- B ++ B ++
- 265
- B ++ B ++
- 266
- A ++ A ++
- 267
- A ++ A ++
- 268
- B ++ A ++
- 269
- A ++ A ++
- 270
- B ++ B ++
- 271
- A ++ A ++
- 272
- A ++ A ++
- 273
- A ++ A ++
- 274
- A ++ A ++
- 275
- A ++ A ++
- 276
- A ++ A ++
- 277
- A ++ A ++
- 278
- A ++ A ++
- 279
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 280
- A ++ A ++
- 281
- B ++ A ++
- 282
- A ++ A ++
- 283
- A ++ A ++
- 284
- A ++ A ++
- 285
- A ++ A ++
- 286
- A ++ A ++
- 287
- A ++ A ++
- 288
- B ++ A ++
- 289
- B ++ A ++
- 290
- A ++ A ++
- 291
- A ++ A ++
- 292
- A ++ A ++
- 293
- A ++ A ++
- 294
- A ++ A ++
- 295
- A ++ A ++
- 296
- A ++ A ++
- 297
- A ++ A ++
- 298
- A ++ A ++
- 299
- B ++ A ++
- 300
- B ++ A ++
- 301
- B ++ A ++
- 302
- A ++ A ++
- 303
- B ++ B ++
- 304
- A ++ A ++
- 305
- A ++ A ++
- 306
- A ++ A ++
- 307
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 308
- A ++ A ++
- 309
- A ++ A ++
- 310
- A ++ A ++
- 311
- A ++ A ++
- 312
- A ++ A ++
- 313
- A ++ A ++
- 314
- A ++ A ++
- 315
- A ++ A ++
- 316
- A ++ A ++
- 317
- A ++ A ++
- 318
- B ++ A ++
- 319
- A ++ A ++
- 320
- A ++ A ++
- 321
- A ++ A ++
- 322
- A ++ A ++
- 323
- B ++ A ++
- 324
- A ++ A ++
- 325
- B ++ A ++
- 326
- A ++ A ++
- 327
- B + B +
- 328
- B + B +
- 329
- A ++ A ++
- 330
- A ++ A ++
- 331
- A ++ A ++
- 332
- B ++ B ++
- 333
- A ++ A ++
- 334
- B + A ++
- 335
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 336
- B ++ A ++
- 337
- A ++ A ++
- 338
- B ++ A ++
- 339
- A ++ A ++
- 340
- A ++ A ++
- 341
- A ++ A ++
- 342
- A ++ A ++
- 343
- B ++ B ++
- 344
- B ++ A ++
- 345
- A ++ A ++
- 346
- A ++ A ++
- 347
- B + B +
- 348
- B + B +
- 349
- A ++ A ++
- 350
- B ++ A ++
- 351
- B + B ++
- 352
- B + B ++
- 353
- B + B ++
- 354
- B + B ++
- 355
- A ++ A ++
- 356
- B ++ A ++
- 357
- B ++ B ++
- 358
- A ++ A ++
- 359
- A ++ A ++
- 360
- B ++ B ++
- 361
- A ++ A ++
- 362
- A ++ A ++
- 363
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 364
- A ++ A ++
- 365
- A ++ A ++
- 366
- A ++ A ++
- 367
- A ++ A ++
- 368
- A ++ A ++
- 369
- B ++ A ++
- 370
- A ++ A ++
- 371
- A ++ A ++
- 372
- B ++ A ++
- 373
- A ++ A ++
- 374
- B ++ B ++
- 375
- A ++ A ++
- 376
- A ++ A ++
- 377
- A ++ A ++
- 378
- A ++ A ++
- 379
- A ++ A ++
- 380
- B ++ A ++
- 381
- A ++ A ++
- 382
- A ++ A ++
- 383
- B ++ B ++
- 384
- B ++ B ++
- 385
- B ++ A ++
- 386
- B ++ A ++
- 387
- B ++ A ++
- 388
- B ++ A ++
- 389
- B ++ A ++
- 390
- A ++ A ++
- 391
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 392
- A ++ A ++
- 393
- A ++ A ++
- 394
- B ++ A ++
- 395
- B ++ A ++
- 396
- B ++ B ++
- 397
- A ++ A ++
- 398
- A ++ A ++
- 399
- A ++ A ++
- 400
- A ++ A ++
- 401
- B ++ A ++
- 402
- A ++ A ++
- 403
- A ++ A ++
- 404
- A ++ A ++
- 405
- A ++ A ++
- 406
- A ++ A ++
- 407
- 408
- A ++ A ++
- 409
- A ++ A ++
- 410
- A ++ A ++
- 411
- A ++ A ++
- 412
- A ++ A ++
- 413
- A ++ A ++
- 414
- A ++ A ++
- 415
- A ++ A ++
- 416
- A ++ A ++
- 417
- A ++ A ++
- 418
- A ++ A ++
- 419
- A ++ A ++
- Compuesto
- Ensayo de viabilidad de MCF7 ER–α en ensayo Western de células (SP1)
- IC50
- Respuesta máxima IC50 Respuesta máxima
- 420
- A ++ A ++
- 421
- A ++ A ++
- 422
- A ++ A ++
- 423
- A ++ A ++
- 424
- B ++ A ++
- 425
- A ++ A ++
- 426
- A ++ A ++
- 427
- A ++ A ++
- 428
- A ++ A ++
- 429
- A ++ A ++
- 430
- A ++ A ++
- 431
- A ++ A ++
- 432
- A ++ A ++
- 433
- A ++ A ++
- 434
- A ++ A ++
- 435
- A ++ A ++
- 436
- A ++ A ++
- 437
- A ++ A ++
- 438
- A ++ A ++
- 439
- A ++ A ++
- 440
- A + A ++
- 441
- A + A ++
- 442
- A ++ A ++
- 443
- A ++ A ++
- 444
- B ++ A ++
- 445
- A ++ A ++
- 446
- A ++ A ++
- 447
- A ++ A ++
Claims (1)
-
imagen1 imagen2 imagen3 imagen4 imagen5 imagen6 imagen7 imagen8 imagen9 imagen10 imagen11
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US410727P | 2002-09-13 | ||
US38365910P | 2010-09-16 | 2010-09-16 | |
US383659P | 2010-09-16 | ||
US41072710P | 2010-11-05 | 2010-11-05 | |
US201161446967P | 2011-02-25 | 2011-02-25 | |
US201161446967P | 2011-02-25 | ||
GB1104288.4A GB2483736B (en) | 2010-09-16 | 2011-03-15 | Estrogen receptor modulators and uses thereof |
GB201104288 | 2011-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2535155T3 true ES2535155T3 (es) | 2015-05-05 |
Family
ID=46599311
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES14155086.3T Active ES2535155T3 (es) | 2010-09-16 | 2011-09-15 | Moduladores de receptores de estrógeno y usos de los mismos |
Country Status (30)
Country | Link |
---|---|
US (4) | US9399646B2 (es) |
EP (2) | EP2616445A4 (es) |
JP (2) | JP5903435B2 (es) |
KR (1) | KR20130136986A (es) |
CN (1) | CN103189361B (es) |
AU (1) | AU2011301952B2 (es) |
BR (1) | BR112013006395A2 (es) |
CA (1) | CA2810094A1 (es) |
CL (1) | CL2013000722A1 (es) |
CO (1) | CO6680708A2 (es) |
CR (1) | CR20130168A (es) |
DK (1) | DK2735562T3 (es) |
EA (1) | EA023947B1 (es) |
ES (1) | ES2535155T3 (es) |
GB (1) | GB2483736B (es) |
HK (1) | HK1192886A1 (es) |
HR (1) | HRP20150433T1 (es) |
HU (1) | HUE025746T2 (es) |
IL (1) | IL224976A (es) |
MX (1) | MX2013002975A (es) |
NZ (1) | NZ607795A (es) |
PE (1) | PE20140191A1 (es) |
PL (1) | PL2735562T3 (es) |
PT (1) | PT2735562E (es) |
RS (1) | RS54026B1 (es) |
SG (1) | SG188551A1 (es) |
SI (1) | SI2735562T1 (es) |
TW (1) | TWI439268B (es) |
WO (2) | WO2012037410A2 (es) |
ZA (1) | ZA201301623B (es) |
Families Citing this family (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2800673A1 (en) | 2010-06-10 | 2011-12-15 | Aragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
WO2013056178A2 (en) | 2011-10-14 | 2013-04-18 | Foundation Medicine, Inc. | Novel estrogen receptor mutations and uses thereof |
US9187460B2 (en) | 2011-12-14 | 2015-11-17 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
MX2014007198A (es) | 2011-12-16 | 2014-10-13 | Olema Pharmaceuticals Inc | Compuestos novedosos de benzopirano, composiciones y usos de los mismos. |
US9499538B2 (en) * | 2012-03-20 | 2016-11-22 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulators and uses thereof |
MX2015011132A (es) | 2013-03-14 | 2015-11-30 | Seragon Pharmaceuticals Inc | Moduladores policiclicos del receptor de estrogenos y sus usos. |
BR112015030595A2 (pt) | 2013-06-19 | 2017-07-25 | Seragon Pharmaceuticals Inc | moduladores de receptor de estrogênio de azetidina e usos dos mesmos |
CA2912853A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
AR097617A1 (es) | 2013-09-13 | 2016-04-06 | Actelion Pharmaceuticals Ltd | Derivados antibacterianos del 2h-indazol |
KR20160085915A (ko) * | 2013-12-06 | 2016-07-18 | 에프. 호프만-라 로슈 아게 | 국소 진행성 또는 전이성 에스트로겐 수용체 양성 유방암을 치료하기 위한 에스트로겐 수용체 조절자 |
JP6407288B2 (ja) | 2013-12-19 | 2018-10-17 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | 抗菌性1h−インダゾール及び1h−インドール誘導体 |
MA39741A (fr) * | 2014-03-13 | 2017-01-18 | Hoffmann La Roche | Combinaisons thérapeutiques avec des modulateurs du récepteur des œstrogènes |
CA2941161A1 (en) | 2014-03-13 | 2015-09-17 | F.Hoffmann-La Roche Ag | Methods and compositions for modulating estrogen receptor mutants |
JP2017524009A (ja) | 2014-08-11 | 2017-08-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | エストロゲン受容体モジュレーターの結晶形態 |
WO2016024350A1 (ja) * | 2014-08-13 | 2016-02-18 | 株式会社エス・ディー・エス バイオテック | 縮合11員環化合物及びそれらを含有する農園芸用殺菌剤 |
JP6359940B2 (ja) * | 2014-10-14 | 2018-07-18 | 国立大学法人 名古屋工業大学 | ジフルオロメチルアセチレン化合物類及びその製造方法 |
JP6768711B2 (ja) | 2015-05-26 | 2020-10-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 複素環式エストロゲン受容体モジュレーター及びその使用 |
EP3981766A1 (en) | 2015-05-29 | 2022-04-13 | Eisai R&D Management Co., Ltd. | Indazole derivatives useful in the treatment of cancer |
CN105061316B (zh) * | 2015-07-17 | 2017-12-22 | 苏州大学 | 稠环类化合物、制备方法和用途 |
KR101771794B1 (ko) | 2015-08-04 | 2017-08-25 | 경북대학교 산학협력단 | 트리아졸로-아릴아크릴로나이트라일 유도체 및 이의 용도 |
CN106518768B (zh) * | 2015-09-15 | 2021-07-02 | 江苏恒瑞医药股份有限公司 | 丙烯酸类衍生物、其制备方法及其在医药上的应用 |
HUE055321T2 (hu) | 2015-10-01 | 2021-11-29 | Olema Pharmaceuticals Inc | Tetrahidro-1H-pirido[3,4-b]indol anti-ösztrogén hatóanyagok |
JP2018533561A (ja) | 2015-10-07 | 2018-11-15 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | (e)−3−(4−((e)−2−(2−クロロ−4−フルオロフェニル)−1−(1h−インダゾール−5−イル)ブタ−1−エン−1−イル)フェニル)アクリル酸を調製するためのプロセス |
WO2017066633A1 (en) | 2015-10-16 | 2017-04-20 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
JP6592197B2 (ja) | 2015-11-12 | 2019-10-16 | 浙江海正薬業股▲ふん▼有限公司Zhejiang Hisun Pharmaceutical CO.,LTD. | アクリル酸誘導体、製造方法、および医薬としてのその使用 |
US10118910B2 (en) | 2015-12-09 | 2018-11-06 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective estrogen receptor downregulators |
KR102605762B1 (ko) | 2016-02-08 | 2023-11-27 | 고완 크롭 프로텍션 리미티드 | 살균성 조성물 |
WO2017138068A1 (ja) | 2016-02-08 | 2017-08-17 | 株式会社エス・ディー・エス バイオテック | 1,2-ベンゼンジメタノール化合物の製造方法 |
EA034994B1 (ru) | 2016-02-15 | 2020-04-15 | Санофи | 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов |
KR102111792B1 (ko) * | 2016-03-25 | 2020-05-18 | 뤄신 바이오테크놀러지 (상하이) 컴퍼니 리미티드 | 에스트로겐 수용체 하향 조절제로서의 치환된 인돌 화합물 |
WO2017197055A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
CN109562113A (zh) | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的螺环降解决定子体 |
WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
CN109789143A (zh) | 2016-07-01 | 2019-05-21 | G1治疗公司 | 基于嘧啶的抗增殖剂 |
CN107973780B (zh) * | 2016-10-21 | 2020-10-09 | 四川科伦博泰生物医药股份有限公司 | 一种取代的烯烃类化合物及其制备方法和用途 |
WO2018081168A2 (en) | 2016-10-24 | 2018-05-03 | The Board Of Trustees Of The University Of Illinois | Benzothiophene-based selective mixed estrogen receptor downregulators |
CN106632144B (zh) * | 2016-10-31 | 2019-02-26 | 浙江省医学科学院 | 一种环丙烷类化合物及其制备方法和应用 |
BR112019009291A2 (pt) * | 2016-11-17 | 2019-07-30 | Sanofi Sa | compostos n-(3-fluoropropil)-pirrolidina substituídos, processos para a sua preparação e usos terapêuticos dos mesmos |
MA46896A (fr) * | 2016-11-24 | 2019-10-02 | Eisai R&D Man Co Ltd | Composés d'alcène tétrasubstitués et leur utilisation |
WO2018098305A1 (en) * | 2016-11-24 | 2018-05-31 | Eisai R&D Management Co., Ltd. | Tetrasubstituted alkene compounds and their use for the treatment of breast cancer |
JP6346368B1 (ja) * | 2016-11-28 | 2018-06-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | インダゾール誘導体の塩及びその結晶 |
CN110177554B (zh) | 2017-01-06 | 2023-06-02 | G1治疗公司 | 用于治疗癌症的组合疗法 |
CN110461853A (zh) | 2017-02-10 | 2019-11-15 | G1治疗公司 | 苯并噻吩雌激素受体调节剂 |
CN109963854B (zh) | 2017-03-16 | 2022-04-12 | 江苏恒瑞医药股份有限公司 | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 |
US11083722B2 (en) | 2017-03-16 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Combination therapies for the treatment of breast cancer |
CN110913861B (zh) | 2017-06-29 | 2024-01-09 | G1治疗公司 | G1t38的形态学形式及其制造方法 |
EP3434272A1 (en) | 2017-07-25 | 2019-01-30 | Sanofi | Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid |
US11034653B2 (en) | 2017-09-25 | 2021-06-15 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Crystal form of estrogen receptor inhibitor and preparation method therefor |
JP2021503478A (ja) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | 組み合わせ治療 |
JP2021519337A (ja) | 2018-03-26 | 2021-08-10 | シー4 セラピューティクス, インコーポレイテッド | Ikarosの分解のためのセレブロン結合剤 |
CN108558838B (zh) * | 2018-04-20 | 2021-04-20 | 苏州凌科特新材料有限公司 | 一种雌激素受体调节剂中间体的生产方法 |
CN108503648B (zh) * | 2018-04-27 | 2020-04-14 | 安徽医科大学 | 苯乙烯基吡唑并嘧啶类化合物、药物组合物及制备方法与用途 |
WO2019225552A1 (en) * | 2018-05-22 | 2019-11-28 | Eisai R&D Management Co., Ltd. | Salts of indazole derivative and crystals thereof |
US10487057B1 (en) * | 2018-07-05 | 2019-11-26 | Landos Biopharma, Inc. | NLRX1 ligands |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
MX2021001857A (es) | 2018-08-17 | 2021-10-13 | Genentech Inc Star | Metodos de diagnostico y terapeuticos para el tratamiento del cancer de mama. |
WO2020051235A1 (en) | 2018-09-04 | 2020-03-12 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
CN112638870A (zh) | 2018-09-07 | 2021-04-09 | 赛诺菲 | 用于制备6-(2,4-二氯苯基)-5-[4-[(3s)-1-(3-氟丙基)吡咯烷-3-基]氧基苯基]-8,9-二氢-7h-苯并[7]轮烯-2-甲酸甲酯的方法 |
US20220017463A1 (en) | 2018-11-28 | 2022-01-20 | Luoxin Pharmaceutical (Shanghai) Co., Ltd. | Salt Form of Estrogen Receptor Downregulator, Crystalline Form Thereof, and Preparation Method Therefor |
CN117430585A (zh) * | 2018-12-17 | 2024-01-23 | 正大天晴药业集团股份有限公司 | 雌激素受体拮抗剂 |
CN113453679A (zh) | 2018-12-20 | 2021-09-28 | C4医药公司 | 靶向蛋白降解 |
AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
EA202192019A1 (ru) | 2019-02-15 | 2021-11-02 | Новартис Аг | Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения |
JP2022532918A (ja) | 2019-05-20 | 2022-07-20 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
EP3978493A4 (en) | 2019-05-24 | 2023-02-01 | Zhejiang Hisun Pharmaceutical Co., Ltd. | CRYSTALLINE FORMS OF ACRYLIC ACID DERIVATIVES, METHOD OF MANUFACTURE THEREOF AND USE THEREOF |
CN110452177A (zh) * | 2019-09-02 | 2019-11-15 | 南通大学 | 一种5-溴-4-氟-1h-吲唑的合成方法 |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
WO2021260528A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
CN116134027A (zh) | 2020-08-03 | 2023-05-16 | 诺华股份有限公司 | 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途 |
WO2022029657A1 (en) * | 2020-08-04 | 2022-02-10 | Novmetahealth Co., Ltd. | Method for treatment of cytokine release syndrome |
WO2022109395A2 (en) | 2020-11-23 | 2022-05-27 | Sanofi | Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer |
EP4251648A2 (en) | 2020-11-24 | 2023-10-04 | Novartis AG | Anti-cd48 antibodies, antibody drug conjugates, and uses thereof |
JP2023553808A (ja) | 2020-11-24 | 2023-12-26 | ノバルティス アーゲー | Mcl-1阻害剤抗体-薬物コンジュゲートおよび使用方法 |
WO2022169780A1 (en) | 2021-02-02 | 2022-08-11 | Les Laboratoires Servier | Selective bcl-xl protac compounds and methods of use |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
CN117440950A (zh) * | 2021-06-27 | 2024-01-23 | 北京盛诺基医药科技股份有限公司 | 一种ERα受体共价结合拮抗剂 |
CN115960082A (zh) * | 2021-10-13 | 2023-04-14 | 长春金赛药业有限责任公司 | 一种四取代的烯烃化合物、其制备方法及其在医药上的应用 |
KR20230146812A (ko) * | 2022-04-13 | 2023-10-20 | 재단법인 대구경북첨단의료산업진흥재단 | 아릴에텐 유도체를 유효성분으로 포함하는 염증성 장질환 치료용 조성물 |
WO2023225320A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2023225336A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
WO2024030968A1 (en) | 2022-08-03 | 2024-02-08 | Brystol-Myers Squibb Company | Compounds for modulating ret protein |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US410727A (en) | 1889-09-10 | beigos | ||
US383659A (en) | 1888-05-29 | Armature for dynamos | ||
FR1390978A (fr) * | 1963-11-20 | 1965-03-05 | Ind Chimique Sa | Procédé de préparation de l'alpha-(thiényl-2) 4-hydroxystilbène et de quelques dérivés et produits obtenus |
EP0002097B1 (en) * | 1977-08-22 | 1981-08-05 | Imperial Chemical Industries Plc | Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
JP3409366B2 (ja) | 1993-06-18 | 2003-05-26 | 東洋インキ製造株式会社 | 有機エレクトロルミネッセンス素子 |
US5681835A (en) * | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
DE19807760A1 (de) | 1997-02-27 | 1998-09-03 | Fuji Electric Co Ltd | Elektrofotografischer Fotoleiter |
UA70925C2 (uk) | 1997-08-15 | 2004-11-15 | Дюк Юнівесіті | Спосіб лікування естрогенстимульованого раку |
DE19801598C2 (de) | 1998-01-17 | 2000-05-11 | Aventis Res & Tech Gmbh & Co | Katalytische Synthese von N-alkylierten Anilinen aus Olefinen und Anilinen |
DE19801597C2 (de) | 1998-01-17 | 2001-05-03 | Aventis Res & Tech Gmbh & Co | Basenkatalysierte Synthese von 1-Aryl-4-(arylethyl)piperazinen aus aromatischen Olefinen und 1-Arylpiperazinen |
TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
GB9929988D0 (en) | 1999-12-17 | 2000-02-09 | Celltech Therapeutics Ltd | Chemical compounds |
US6528681B2 (en) | 2000-04-05 | 2003-03-04 | Bristol-Meyers Squibb Pharma Company | Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
WO2003016270A2 (en) * | 2001-08-11 | 2003-02-27 | Bristol-Myers Squibb Pharma Company | Selective estrogen receptor modulators |
JP4562523B2 (ja) | 2002-06-06 | 2010-10-13 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | トロンボポエチン疑似体 |
ATE399775T1 (de) * | 2003-10-08 | 2008-07-15 | Smithkline Beecham Corp | Triphenylethyleneverbindungen als selektive modulatoren des östrogenrezeptors |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
US20070292545A1 (en) | 2005-10-18 | 2007-12-20 | Aaron Monte | Anti-infective agents and methods of use |
WO2006081230A2 (en) | 2005-01-26 | 2006-08-03 | Schering Corporation | 3-(indazol-5-yl)-(1,2, 4) triazine derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
KR20080045705A (ko) | 2005-08-15 | 2008-05-23 | 테크니온 리서치 엔드 디벨로프먼트 화운데이션 엘티디. | 인쇄가능 재료 |
WO2007062151A2 (en) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Chemical compounds |
JP2010508358A (ja) | 2006-11-01 | 2010-03-18 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、AP−1、および/またはNF−κB活性の調節剤、並びにその使用 |
JP2008156313A (ja) | 2006-12-26 | 2008-07-10 | Fyuuensu:Kk | アミロイド疾患の治療およびモニタリングのための薬剤 |
GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
JP5223362B2 (ja) | 2008-02-07 | 2013-06-26 | コニカミノルタビジネステクノロジーズ株式会社 | 光電変換素子及び太陽電池 |
WO2009131654A2 (en) | 2008-04-21 | 2009-10-29 | North Carolina State University | Inhibition and dispersion of bacterial biofilms with imidazole-triazole derivatives |
AR074199A1 (es) | 2008-11-20 | 2010-12-29 | Glaxosmithkline Llc | Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer. |
US20110294668A1 (en) | 2008-12-08 | 2011-12-01 | North Carolina State University | Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives |
WO2010107474A1 (en) | 2009-03-16 | 2010-09-23 | The Research Foundation Of State University Of New York | Antiestrogens for breast cancer therapy |
WO2010144959A1 (en) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
-
2011
- 2011-03-15 GB GB1104288.4A patent/GB2483736B/en active Active
- 2011-09-15 MX MX2013002975A patent/MX2013002975A/es active IP Right Grant
- 2011-09-15 US US13/821,190 patent/US9399646B2/en active Active
- 2011-09-15 US US13/234,035 patent/US8299112B2/en active Active
- 2011-09-15 HU HUE14155086A patent/HUE025746T2/en unknown
- 2011-09-15 BR BR112013006395A patent/BR112013006395A2/pt not_active IP Right Cessation
- 2011-09-15 SI SI201130472T patent/SI2735562T1/sl unknown
- 2011-09-15 WO PCT/US2011/051843 patent/WO2012037410A2/en active Application Filing
- 2011-09-15 CN CN201180051863.6A patent/CN103189361B/zh active Active
- 2011-09-15 CA CA2810094A patent/CA2810094A1/en not_active Abandoned
- 2011-09-15 PT PT141550863T patent/PT2735562E/pt unknown
- 2011-09-15 PL PL14155086T patent/PL2735562T3/pl unknown
- 2011-09-15 EP EP11825982.9A patent/EP2616445A4/en not_active Withdrawn
- 2011-09-15 NZ NZ607795A patent/NZ607795A/en not_active IP Right Cessation
- 2011-09-15 PE PE2013000500A patent/PE20140191A1/es not_active Application Discontinuation
- 2011-09-15 DK DK14155086.3T patent/DK2735562T3/en active
- 2011-09-15 JP JP2013529347A patent/JP5903435B2/ja active Active
- 2011-09-15 EA EA201370066A patent/EA023947B1/ru not_active IP Right Cessation
- 2011-09-15 EP EP14155086.3A patent/EP2735562B2/en active Active
- 2011-09-15 SG SG2013019153A patent/SG188551A1/en unknown
- 2011-09-15 KR KR1020137008141A patent/KR20130136986A/ko not_active Application Discontinuation
- 2011-09-15 AU AU2011301952A patent/AU2011301952B2/en not_active Ceased
- 2011-09-15 WO PCT/US2011/051845 patent/WO2012037411A2/en active Application Filing
- 2011-09-15 RS RS20150339A patent/RS54026B1/en unknown
- 2011-09-15 ES ES14155086.3T patent/ES2535155T3/es active Active
- 2011-09-15 TW TW100133283A patent/TWI439268B/zh not_active IP Right Cessation
-
2012
- 2012-09-13 US US13/613,467 patent/US8455534B2/en active Active
-
2013
- 2013-02-28 IL IL224976A patent/IL224976A/en active IP Right Grant
- 2013-03-04 ZA ZA2013/01623A patent/ZA201301623B/en unknown
- 2013-03-12 CO CO13049146A patent/CO6680708A2/es unknown
- 2013-03-15 CL CL2013000722A patent/CL2013000722A1/es unknown
- 2013-04-12 CR CR20130168A patent/CR20130168A/es unknown
- 2013-11-05 HK HK14105917.3A patent/HK1192886A1/xx active IP Right Maintenance
-
2015
- 2015-04-21 HR HRP20150433TT patent/HRP20150433T1/hr unknown
-
2016
- 2016-03-11 JP JP2016048717A patent/JP2016155832A/ja active Pending
- 2016-06-17 US US15/186,246 patent/US9868704B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2535155T3 (es) | Moduladores de receptores de estrógeno y usos de los mismos | |
AU2008276236B2 (en) | Compounds and methods for modulating FXR | |
JP7286825B2 (ja) | Cyp11a1(チトクロムp450モノオキシゲナーゼ11a1)阻害剤としてのピラン誘導体 | |
ES2508765T3 (es) | Procedimiento para producir un compuesto de 5-hidroxi-4-tiometilpirazol | |
JP6966423B2 (ja) | 縮合環ピリミジンアミノ誘導体、その製造方法、中間体、薬学的組成物及び応用 | |
CA2651373A1 (en) | Compounds and methods for modulating fxr | |
US10336697B2 (en) | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | |
WO2004013135A1 (en) | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors | |
WO2014036897A1 (zh) | 咪唑啉类衍生物、其制备方法及其在医药上的应用 | |
JP2012507483A (ja) | Bri−モジュレータとしての置換されたジスルホンアミド | |
KR20140021600A (ko) | 류코트리엔 생성의 벤조디옥산 억제제 | |
TW200524896A (en) | Novel indazole derivative | |
EP2074114A1 (en) | Pyrimidinones as casein kinase ii (ck2) modulators | |
KR20000010905A (ko) | 도파민 d3 수용체의 조절제로서의 테트라히드로이소퀴놀린유도체 | |
TW201329058A (zh) | 多環類衍生物、其製備方法及其在醫藥上的應用 | |
KR20130018809A (ko) | 술폰아미도―벤조푸란 유도체의 제조 방법 | |
CA2685888A1 (en) | Substituted heterocyclic derivatives and their pharmaceutical use and compositions | |
SK279472B6 (sk) | Fenoxy- a fenoxyalkylpiperidíny, farmaceutický pro | |
CA2338044A1 (en) | Phthalazine derivatives phosphodiesterase 4 inhibitors | |
EP2402330B1 (en) | Pyrazolone-derivatives as PDE4 inhibitors | |
AU2021294035A1 (en) | Sulphonamide compounds | |
WO2004069828A1 (ja) | ピペリジン化合物およびその医薬用途 | |
WO2015012110A1 (ja) | C-グリコシド誘導体の製造方法 | |
CA2684701A1 (en) | Pyrazoles useful in the treatment of inflammation | |
CN111196804B (zh) | TGF-βR1抑制剂及其应用 |